Author: "Ninios I" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Ninios I"' showing total 29 results

Start Over Author "Ninios I"

29 results on '"Ninios I"'

1. 470 Cardiac Computed Tomography Prior And After A Transcatheter Occlusion Of An Aortic Pseudoaneurysm With The Amplatzer Device: A Case Report

Author: Evangelou, S., primary, Ninios, V., additional, Ninios, I., additional, Ioannides, A., additional, and Roubelakis, A., additional
Published: 2022
Full Text: View/download PDF

2. Impending total AV-block in chronic bifascicular block -Risk assessment via symptoms and 12 lead ECG

Author: Zarse, M., Goebbert, K., Bogossian, H., Karossiene, Z., Stegelmeyer, J., Ninios, I., Kloppe, A., and Lemke, B.
Published: 2011

3. The transseptal acces increases safety and efficacy of substrate modification for ventricular tachycardia

Author: Zarse, M., Suleimann, H., Bogossian, H., Stegelmeyer, J., Ninios, I., Karosienne, Z., Kloppe, A., and Lemke, B.
Published: 2011

4. A new combined stylet/guide wire-tool for left ventricular lead placement for cardiac resynchronisation therapy

Author: Kloppe, A., Mijic, D., Bogossian, H., Ninios, I., Zarse, M., and Lemke, B.
Published: 2011

5. Fractured Bioprosthetic Pulmonary Valve Identified By Cardiac Computed Tomography Followed By Transcatheter Replacement

Author: Evangelou, S., primary, Ninios, I., additional, Ioannides, A., additional, and Ninios, V., additional
Published: 2021
Full Text: View/download PDF

6. Prevalence, clinical correlates and treatment of permanent atrial fibrillation among the elderly: Insights from the first prospective population-based study in rural Greece

Author: Ninios, I. Bogossian, H. Zarse, M. Lazaridou, F. Dimitriadis, K. Ninios, V. Lemke, B. Louridas, G.
Abstract: To investigate the prevalence of permanent atrial fibrillation (AF), its clinical associated conditions and treatment status in the elderly population in rural Greece. 720 people (46.1% males) older than 65 years (mean age: 72.5 ± 5.7 years) living in four villages in rural Greece were screened with an electrocardiogram (response rate: 90.5%) for the presence of permanent AF. They underwent a physical examination, including blood pressure (BP) measurement, and body mass index (BMI) calculation, in addition to an interview about their medical history, physical activity, smoking habits, alcohol consumption and medication use. Subjects with AF for whom anticoagulants were contraindicated were identified and stroke risk stratification was performed using the CHADS2 algorithm. The prevalence of permanent AF was 5% (6.6% among men and 3.6% among women) and it increased with age. In the entire population, ECG evidence of myocardial ischaemia and ventricular premature beats were independently associated with the presence of permanent AF (OR 5.266; 95% CI 2.22-12.49, P = 0.0001 and OR 2.61; 95% CI 1.059-6.432, P = 0.037, respectively), while female sex was independently associated with the absence of the AF (OR 0.327; CI 0.147-0.729, P = 0.006). From those patients who were eligible for anticoagulation, 40.6% were treated with anticoagulants, 34.3% were given antiplatelets therapy and the rest received no antithrombotic treatment. This is the first prospective study demonstrating the prevalence, clinical correlates and treatment status of permanent AF in Greece. These results confirm the high prevalence of permanent AF among the elderly and underscore the issue regarding anticoagulants underutilization. © 2009 Springer Science+Business Media, LLC.
Published: 2010

7. Poster Session 3

Author: Fabbri, G. M. T., primary, Baldasseroni, S., additional, Panuccio, D., additional, Zoni Berisso, M., additional, Scherillo, M., additional, Lucci, D., additional, Di Pasquale, G., additional, Mathieu, G., additional, Burazor, I., additional, Burazor, M., additional, Perisic, Z., additional, Atanaskovic, V., additional, Erakovic, V., additional, Stojkovic, A., additional, Vogtmann, T., additional, Schoebel, C., additional, Sogorski, S., additional, Sebert, M., additional, Schaarschmidt, J., additional, Fietze, I., additional, Baumann, G., additional, Penzel, T., additional, Mornos, C., additional, Ionac, A., additional, Cozma, D., additional, Dragulescu, D., additional, Mornos, A., additional, Petrescu, L., additional, Pescariu, L., additional, Brembilla-Perrot, B., additional, Khachab, H., additional, Lamberti, F., additional, Bellini, C., additional, Remoli, R., additional, Cogliandro, T., additional, Nardo, R., additional, Bellusci, F., additional, Mazzuca, V., additional, Gaspardone, A., additional, Aguinaga Arrascue, L. E., additional, Bravo, A., additional, Garcia Freire, P., additional, Gallardo, P., additional, Hasbani, E., additional, Quintana, R., additional, Dantur, J., additional, Inoue, K., additional, Ueoka, A., additional, Tsubakimoto, Y., additional, Sakatani, T., additional, Matsuo, A., additional, Fujita, H., additional, Kitamura, M., additional, Wegrzynowska, M., additional, Konduracka, E., additional, Pietrucha, A. Z., additional, Mroczek-Czernecka, D., additional, Paradowski, A., additional, Bzukala, I., additional, Nessler, J., additional, Igawa, O., additional, Adachi, M., additional, Atarashi, H., additional, Kusama, Y., additional, Kodani, E., additional, Okazaki, R., additional, Nakagomi, A., additional, Endoh, Y., additional, Baez-Escudero, J. L., additional, Dave, A. S., additional, Sasaridis, C. M., additional, Valderrabano, M., additional, Tilz, R., additional, Bai, R., additional, Di Biase, L., additional, Gallinghouse, G. J., additional, Gibson, D., additional, Pisapia, A., additional, Wazni, O., additional, Natale, A., additional, Arujuna, A., additional, Karim, R., additional, Rinaldi, A., additional, Cooklin, M., additional, Rhode, K., additional, Razavi, R., additional, O'neill, M., additional, Gill, J., additional, Kusa, S., additional, Komatsu, Y., additional, Kakita, K., additional, Takayama, K., additional, Taniguchi, H., additional, Otomo, K., additional, Iesaka, Y., additional, Ammar, S., additional, Reents, T., additional, Fichtner, S., additional, Wu, J., additional, Zhu, P., additional, Kolb, C., additional, Hessling, G., additional, Deisenhofer, I., additional, Gilbert, G., additional, Mohanty, P., additional, Cunningham, J., additional, Metz, T., additional, Horton, R., additional, Tao, S., additional, Yamauchi, Y., additional, Okada, H., additional, Maeda, S., additional, Obayashi, T., additional, Isobe, M., additional, Chan, J., additional, Johar, S., additional, Wong, T., additional, Markides, V., additional, Hussain, W., additional, Konstantinidou, M., additional, Wissner, E., additional, Fuernkranz, A., additional, Yoshiga, Y., additional, Metzner, A., additional, Kuck, K.- H., additional, Ouyang, F., additional, Kettering, K., additional, Gramley, F., additional, Mollnau, H., additional, Weiss, C., additional, Bardeleben, S., additional, Biasco, L., additional, Scaglione, M., additional, Caponi, D., additional, Di Donna, P., additional, Sergi, D., additional, Cerrato, N., additional, Blandino, A., additional, Gaita, F., additional, Fiala, M., additional, Wichterle, D., additional, Sknouril, L., additional, Bulkova, V., additional, Chovancik, J., additional, Nevralova, R., additional, Pindor, J., additional, Januska, J., additional, Choi, J. I., additional, Ban, J. E., additional, Yasutsugu, N., additional, Park, J. S., additional, Jung, J. S., additional, Lim, H. E., additional, Park, S. W., additional, Kim, Y. H., additional, Kuhne, M., additional, Reichlin, T., additional, Ammann, P., additional, Schaer, B., additional, Osswald, S., additional, Sticherling, C., additional, Ohe, M., additional, Goya, M., additional, Hiroshima, K., additional, Hayashi, K., additional, Makihara, Y., additional, Nagashima, M., additional, Fukunaga, M., additional, An, Y., additional, Dorwarth, U., additional, Schmidt, M., additional, Wankerl, M., additional, Krieg, J., additional, Straube, F., additional, Hoffmann, E., additional, Kathan, S., additional, Defaye, P., additional, Mbaye, A., additional, Cassagneau, R., additional, Gagniere, V., additional, Jacon, P., additional, Pokushalov, E., additional, Romanov, A., additional, Artemenko, S., additional, Shabanov, V., additional, Elesin, D., additional, Stenin, I., additional, Turov, A., additional, Losik, D., additional, Kondo, K., additional, Miake, J., additional, Yano, A., additional, Ogura, K., additional, Kato, M., additional, Shigemasa, C., additional, Sekiguchi, Y., additional, Tada, H., additional, Yoshida, K., additional, Naruse, Y., additional, Yamasaki, H., additional, Igarashi, M., additional, Machino, T., additional, Aonuma, K., additional, Chen, S., additional, Liu, S., additional, Chen, G., additional, Meng, W., additional, Zhang, F., additional, Yan, Y., additional, Sciarra, L., additional, Dottori, S., additional, Lanzillo, C., additional, De Ruvo, E., additional, De Luca, L., additional, Minati, M., additional, Lioy, E., additional, Calo', L., additional, Lin, J., additional, Nie, Z., additional, Zhu, M., additional, Wang, X., additional, Zhao, J., additional, Hu, W., additional, Tao, H., additional, Ge, J., additional, Johansson, B., additional, Houltz, B., additional, Edvardsson, N., additional, Schersten, H., additional, Karlsson, T., additional, Wandt, B., additional, Berglin, E., additional, Hoyt, R. H., additional, Jenson, B. P., additional, Trines, S. A. I. P., additional, Braun, J., additional, Tjon Joek Tjien, A., additional, Zeppenfeld, K., additional, Tavilla, G., additional, Klautz, R. J. M., additional, Schalij, M. J., additional, Krausova, R., additional, Cihak, R., additional, Peichl, P., additional, Kautzner, J., additional, Pirk, J., additional, Skalsky, I., additional, Maly, J., additional, Imai, K., additional, Sueda, T., additional, Orihashi, K., additional, Picarra, B. C., additional, Santos, A. R., additional, Dionisio, P., additional, Semedo, P., additional, Matos, R., additional, Leitao, M., additional, Banha, M., additional, Trinca, M., additional, Elder, D. H. J., additional, George, J., additional, Jain, R., additional, Lang, C. C., additional, Choy, A. M., additional, Konert, M., additional, Loescher, S., additional, Hartmann, A., additional, Aversa, E., additional, Chirife, R., additional, Sztyglic, E., additional, Mazzetti, H., additional, Mascheroni, O., additional, Tentori, M. C., additional, Pop, R. M., additional, Margulescu, A. D., additional, Dulgheru, R., additional, Enescu, O., additional, Siliste, C., additional, Vinereanu, D., additional, Menezes Junior, A., additional, Castro Carneiro, A. R., additional, De Oliveira, B. L., additional, Shah, A. N., additional, Kantharia, B., additional, De Lucia, R., additional, Soldati, E., additional, Segreti, L., additional, Di Cori, A., additional, Zucchelli, G., additional, Viani, S., additional, Paperini, L., additional, Bongiorni, M. G., additional, Kutarski, A., additional, Czajkowski, M., additional, Pietura, R., additional, Malecka, B., additional, Heintze, J., additional, Eckardt, L., additional, Bauer, A., additional, Meine, M., additional, Van Erven, L., additional, Bloch Thomsen, P. E., additional, Lopez Chicharro, M. P., additional, Merhi, O., additional, Soga, Y., additional, Andou, K., additional, Nobuyoshi, M., additional, Gonzalez-Mansilla, A., additional, Martin-Asenjo, R., additional, Unzue, L., additional, Torres, J., additional, Garralda, E., additional, Coma, R. R., additional, Rodriguez Garcia, J. E., additional, Yaegashi, T., additional, Furusho, H., additional, Kato, T., additional, Chikata, A., additional, Takashima, S., additional, Usui, S., additional, Takamura, M., additional, Kaneko, S., additional, Chudzik, M., additional, Mitkowski, P., additional, Przybylski, A., additional, Lewek, J., additional, Smukowski, T., additional, Maciag, A., additional, Castrejon Castrejon, S., additional, Perez-Silva, A., additional, Estrada, A., additional, Doiny, D., additional, Ortega, M., additional, Lopez-Sendon, J. L., additional, Merino, J. L., additional, O'mahony, C., additional, Coats, C., additional, Cardona, M., additional, Garcia, A., additional, Calcagnino, M., additional, Lachmann, R., additional, Hughes, D., additional, Elliott, P. M., additional, Conti, S., additional, Pruiti, G. P., additional, Puzzangara, E., additional, Romano, S. A., additional, Di Grazia, A., additional, Ussia, G. P., additional, Tamburino, C., additional, Calvi, V., additional, Radinovic, A., additional, Sala, S., additional, Latib, A., additional, Mussardo, M., additional, Sora, S., additional, Paglino, G., additional, Gullace, M., additional, Colombo, A., additional, Ohlow, M.- A. G., additional, Lauer, B., additional, Wagner, A., additional, Schreiber, M., additional, Buchter, B., additional, Farah, A., additional, Fuhrmann, J. T., additional, Geller, J. C., additional, Nascimento Cardoso, R. M., additional, Batista Sa, L. A., additional, Campos Filho, L. F. C., additional, Rodrigues, S. V., additional, Dutra, M. V. F., additional, Borges, T. R. S. A., additional, Portilho, D. R., additional, Deering, T., additional, Bernardes, A., additional, Veiga, A., additional, Gartenlaub, O., additional, Goncalves, A., additional, Jimenez, A., additional, Rousseauplasse, A., additional, Deharo, J. C., additional, Striekwold, H., additional, Gosselin, G., additional, Sitbon, H., additional, Martins, V., additional, Molon, G., additional, Ayala-Paredes, F., additional, Sancho-Tello, M. J., additional, Fazal, I. A., additional, Brady, S., additional, Cronin, J., additional, Mcnally, S., additional, Tynan, M., additional, Plummer, C. J., additional, Mccomb, J. M., additional, Val-Mejias, J. E., additional, Oliveira, R. M., additional, Costa, R., additional, Martinelli Filho, M., additional, Silva, K. R., additional, Menezes, L. M., additional, Tamaki, W. T., additional, Mathias, W., additional, Stolf, N. A. G., additional, Misawa, T., additional, Ohta, I., additional, Shishido, T., additional, Miyasita, T., additional, Miyamoto, T., additional, Nitobe, J., additional, Watanabe, T., additional, Kubota, I., additional, Thibault, B., additional, Ducharme, A., additional, Simpson, C., additional, Stuglin, C., additional, Gagne, C. E., additional, Williams, R., additional, Mcnicoll, S., additional, Silvetti, M. S., additional, Drago, F., additional, Penela, D., additional, Bijnens, B., additional, Doltra, A., additional, Silva, E., additional, Berruezo, A., additional, Mont, L., additional, Sitges, M., additional, Mcintosh, R., additional, Baumann, O., additional, Raju, P., additional, Gurunathan, S., additional, Furniss, S., additional, Patel, N., additional, Sulke, N., additional, Lloyd, G., additional, Mor, M., additional, Dror, S., additional, Tsadok, Y., additional, Bachner-Hinenzon, N., additional, Katz, A., additional, Liel-Cohen, N., additional, Etzion, Y., additional, Mlynarski, R., additional, Mlynarska, A., additional, Wilczek, J., additional, Sosnowski, M., additional, Sinha, A. M., additional, Sinha, D., additional, Noelker, G., additional, Brachmann, J., additional, Weidemann, F., additional, Ertl, G., additional, Jones, M., additional, Searle, N., additional, Cocker, M., additional, Ilsley, E., additional, Foley, P., additional, Khiani, R., additional, Nelson, K. E., additional, Turley, A. J., additional, Owens, W. A., additional, James, S. A., additional, Linker, N. J., additional, Velagic, V., additional, Cikes, M., additional, Pezo Nikolic, B., additional, Puljevic, D., additional, Separovic-Hanzevacki, J., additional, Lovric-Bencic, M., additional, Biocina, B., additional, Milicic, D., additional, Kawata, H., additional, Chen, L., additional, Phan, H., additional, Anand, K., additional, Feld, G., additional, Birgesdotter-Green, U., additional, Fernandez Lozano, I., additional, Mitroi, C., additional, Toquero Ramos, J., additional, Castro Urda, V., additional, Monivas Palomero, V., additional, Corona Figueroa, A., additional, Hernandez Reina, L., additional, Alonso Pulpon, L., additional, Gate-Martinet, A., additional, Da Costa, A., additional, Rouffiange, P., additional, Cerisier, A., additional, Bisch, L., additional, Romeyer-Bouchard, C., additional, Isaaz, K., additional, Morales, M.- A., additional, Bianchini, E., additional, Startari, U., additional, Faita, F., additional, Bombardini, T., additional, Gemignani, V., additional, Piacenti, M., additional, Adhya, S., additional, Kamdar, R. H., additional, Millar, L. M., additional, Burchardt, C., additional, Murgatroyd, F. D., additional, Klug, D., additional, Kouakam, C., additional, Guedon-Moreau, L., additional, Marquie, C., additional, Benard, S., additional, Kacet, S., additional, Cortez-Dias, N., additional, Carrilho-Ferreira, P., additional, Silva, D., additional, Goncalves, S., additional, Valente, M., additional, Marques, P., additional, Carpinteiro, L., additional, Sousa, J., additional, Keida, T., additional, Nishikido, T., additional, Fujita, M., additional, Chinen, T., additional, Kikuchi, T., additional, Nakamura, K., additional, Ohira, H., additional, Takami, M., additional, Anjo, D., additional, Meireles, A., additional, Gomes, C., additional, Roque, C., additional, Pinheiro Vieira, A., additional, Lagarto, V., additional, Reis, H., additional, Torres, S., additional, Ortega, D. F., additional, Barja, L. D., additional, Montes, J. P., additional, Logarzo, E., additional, Bonomini, P., additional, Mangani, N., additional, Paladino, C., additional, Chwyczko, T., additional, Smolis-Bak, E., additional, Sterlinski, M., additional, Pytkowski, M., additional, Firek, B., additional, Jankowska, A., additional, Szwed, H., additional, Nakajima, I., additional, Noda, T., additional, Okamura, H., additional, Satomi, K., additional, Aiba, T., additional, Shimizu, W., additional, Aihara, N., additional, Kamakura, S., additional, Brzozowski, W., additional, Tomaszewski, A., additional, Wysokinski, A., additional, Bertoldi, E. G., additional, Rohde, L. E., additional, Zimerman, L. I., additional, Pimentel, M., additional, Polanczyk, C. A., additional, Boriani, G., additional, Lunati, M., additional, Gasparini, M., additional, Landolina, M., additional, Lonardi, G., additional, Pecora, D., additional, Santini, M., additional, Valsecchi, S., additional, Rubinstein, B. J., additional, Wang, D. Y., additional, Cabreriza, S. E., additional, Richmond, M. E., additional, Rusanov, A., additional, Quinn, T. A., additional, Cheng, B., additional, Spotnitz, H. M., additional, Kristiansen, H. M., additional, Vollan, G., additional, Hovstad, T., additional, Keilegavlen, H., additional, Faerestrand, S., additional, Brigesdotter-Green, U., additional, Nawar, A. M. R., additional, Ragab, D. A. L. I. A., additional, Eluhsseiny, R. A. N. I. A., additional, Abdelaziz, A. H. M. E. D., additional, Nof, E., additional, Abu Shama, R., additional, Buber, J., additional, Kuperstein, R., additional, Feinberg, M. S., additional, Barlev, D., additional, Eldar, M., additional, Glikson, M., additional, Badran, H., additional, Samir, R., additional, Tawfik, M., additional, Amin, M., additional, Eldamnhoury, H., additional, Khaled, S., additional, Tolosana, J. M., additional, Martin, A. M., additional, Hernandez-Madrid, A., additional, Macias, A., additional, Fernandez-Lozano, I., additional, Osca, J., additional, Quesada, A., additional, Padeletti, L., additional, Botto, G. L., additional, De Santo, T., additional, Szwed, A., additional, Martinez, J. G., additional, Degand, B., additional, Villani, G. Q., additional, Leclercq, C., additional, Ritter, P., additional, Watanabe, I., additional, Nagashima, K., additional, Okumura, Y., additional, Kofune, M., additional, Ohkubo, K., additional, Nakai, T., additional, Hirayama, A., additional, Mikhaylov, E., additional, Vander, M., additional, Lebedev, D., additional, Zarse, M., additional, Suleimann, H., additional, Bogossian, H., additional, Stegelmeyer, J., additional, Ninios, I., additional, Karosienne, Z., additional, Kloppe, A., additional, Lemke, B., additional, John, S., additional, Gaspar, T., additional, Rolf, S., additional, Sommer, P., additional, Hindricks, G., additional, Piorkowski, C., additional, Fernandez-Armenta, J., additional, Mont, L. L., additional, Zeljko, H., additional, Andreu, D., additional, Herzcku, C., additional, Boussy, T., additional, Brugada, J., additional, Obayahi, T., additional, Hegrenes, J., additional, Lim, E., additional, Mediratta, V., additional, Bautista, R., additional, Teplitsky, L., additional, Van Huls Van Taxis, C. F. B., additional, Wijnmaalen, A. P., additional, Gawrysiak, M., additional, Schuijf, J. D., additional, Bax, J. J., additional, Huo, Y., additional, Richter, S., additional, Arya, A., additional, Bollmann, A., additional, Akca, F., additional, Bauernfeind, T., additional, Schwagten, B., additional, De Groot, N. M. S., additional, Jordaens, L., additional, Szili-Torok, T., additional, Miller, S., additional, Kastner, G., additional, Maury, P., additional, Della Bella, P., additional, Delacretaz, E., additional, Sacher, F., additional, Maccabelli, G., additional, Brenner, R., additional, Rollin, A., additional, Jais, P., additional, Vergara, P., additional, Trevisi, N., additional, Ricco, A., additional, Petracca, F., additional, Bisceglia, C., additional, Baratto, F., additional, Salguero Bodes, R., additional, Fontenla Cerezuela, A., additional, De Riva Silva, M., additional, Lopez Gil, M., additional, Mejia Martinez, E., additional, Jurado Roman, A., additional, Montero Alvarez, M., additional, Arribas Ynsaurriaga, F., additional, Baszko, A., additional, Krzyzanowski, K., additional, Bobkowski, W., additional, Surmacz, R., additional, Zinka, E., additional, Siwinska, A., additional, Szyszka, A., additional, Perez Silva, A., additional, Estrada Mucci, A., additional, Ortega Molina, M., additional, Lopez Sendon, J. L., additional, Merino Llorens, J. L., additional, Kaitani, K., additional, Hanazawa, K., additional, Izumi, C., additional, Nakagawa, Y., additional, Yamanaka, I., additional, Hirahara, T., additional, Sugawara, Y., additional, Suga, C., additional, Ako, J., additional, Momomura, S., additional, Galizio, N., additional, Gonzalez, J., additional, Robles, F., additional, Palazzo, A., additional, Favaloro, L., additional, Diez, M., additional, Guevara, E., additional, Fernandez, A., additional, Greenberg, S., additional, Epstein, A., additional, Goldman, D. S., additional, Sangli, C., additional, Keeney, J. A., additional, Lee, K., additional, Piers, S. R. D., additional, Van Rees, J. B., additional, Thijssen, J., additional, Borleffs, C. J. W., additional, Van Der Velde, E. T., additional, Leclercq, C. H., additional, Hero, M., additional, Mizobuchi, M., additional, Enjoji, Y., additional, Yazaki, Y., additional, Shibata, K., additional, Funatsu, A., additional, Kobayashi, T., additional, Nakamura, S., additional, Amit, G., additional, Pertzov, B., additional, Zahger, D., additional, Medesani, L., additional, Rana, R., additional, Albano, F., additional, Fraguas, H., additional, Pedersen, S. S., additional, Hoogwegt, M. T., additional, Theuns, D. A. M. J., additional, Van Den Broek, K. C., additional, Tekle, F. B., additional, Habibovic, M., additional, Alings, M., additional, Van Der Voort, P., additional, Denollet, J., additional, Vrazic, H., additional, Jilek, C., additional, Lesevic, H., additional, Tzeis, S., additional, Semmler, V., additional, Gold, M. R., additional, Burke, M. C., additional, Bardy, G. H., additional, Varma, N., additional, Pavri, B., additional, Stambler, B., additional, Michalski, J., additional, Investigators, T. R. U. S. T., additional, Safak, E., additional, Schmitz, D., additional, Konorza, T., additional, Wende, C., additional, Schirdewan, A., additional, Neuzner, J., additional, Simmers, T., additional, Erglis, A., additional, Gradaus, R., additional, Goetzke, J., additional, Coutrot, L., additional, Goehl, K., additional, Bazan Gelizo, V., additional, Grau, N., additional, Valles, E., additional, Felez, M., additional, Sanjuas, C., additional, Bruguera, J., additional, Marti-Almor, J., additional, Chu, S. Y., additional, Li, P. W., additional, Ding, W. H., additional, Schukro, C., additional, Leitner, L., additional, Siebermair, J., additional, Stix, G., additional, Pezawas, T., additional, Kastner, J., additional, Wolzt, M., additional, Schmidinger, H., additional, Behar, N. A. T. H. A. L. I. E., additional, Kervio, G., additional, Petit, B., additional, Maison-Balnche, P., additional, Bodi, S., additional, Mabo, P., additional, Foley, P. W. X., additional, Mutch, E., additional, Brashaw-Smith, J., additional, Ball, L., additional, Leyva, F., additional, Kim, D. H., additional, Lee, M. J., additional, Lee, W. S., additional, Park, S. D., additional, Shin, S. H., additional, Woo, S. I., additional, Kwan, J., additional, Park, K. S., additional, Munetsugu, Y., additional, Tanno, K., additional, Kikuchi, M., additional, Ito, H., additional, Miyoshi, F., additional, Kawamura, M., additional, Kobayashi, Y., additional, Man, S., additional, Algra, A. M., additional, Schreurs, C. A., additional, Van Der Wall, E. E., additional, Cannegieter, S. C., additional, Swenne, C. A., additional, Iitsuka, K., additional, Kondo, T., additional, Goebbert, K., additional, Karossiene, Z., additional, Goldman, D., additional, Kallen, B., additional, Kerpi, E., additional, Sardo, J., additional, Arsenos, P., additional, Gatzoulis, K., additional, Manis, G., additional, Dilaveris, P., additional, Tsiachris, D., additional, Mytas, D., additional, Asimakopoulos, S., additional, Stefanadis, C., additional, Sideris, S., additional, Kartsagoulis, E., additional, Barbosa, O., additional, Marocolo Junior, M., additional, Silva Cortes, R., additional, Moraes Brandolis, R. A., additional, Oliveira, L. F., additional, Pertili Rodrigues De Resende, L. A., additional, Vieira Da Silva, M. A., additional, Dias Da Silva, V. J., additional, Hegazy, R. A., additional, Sharaf, I. A., additional, Fadel, F., additional, Bazaraa, H., additional, Esam, R., additional, Deshko, M. S., additional, Snezhitsky, V. A., additional, Stempen, T. P., additional, Kuroki, K., additional, Igawa, M., additional, Kuga, K., additional, Ferreira Santos, L., additional, Dionisio, T., additional, Nunes, L., additional, Machado, J., additional, Castedo, S., additional, Henriques, C., additional, Matos, A., additional, Oliveira Santos, J., additional, Kraaier, K., additional, Olimulder, M. A. G. M., additional, Galjee, M. A., additional, Van Dessel, P. F. H. M., additional, Van Der Palen, J., additional, Wilde, A. A. M., additional, Scholten, M. F., additional, Chouchou, F., additional, Poupard, L., additional, Philippe, C., additional, Court-Fortune, I., additional, Barthelemy, J.- C., additional, Roche, F., additional, Dolgoshey, T. S., additional, Madekina, G. A., additional, Sugiura, S., additional, Fujii, E., additional, Senga, M., additional, Dohi, K., additional, Sugiura, E., additional, Nakamura, M., additional, Ito, M., additional, Eitel, C., additional, Mendell, J., additional, Lasseter, K., additional, Shi, M., additional, Urban, L., additional, Hatala, R., additional, Hlivak, P., additional, De Melis, M., additional, Garutti, C., additional, Corbucci, G., additional, Mlcochova, H., additional, Maxian, R., additional, Arbelo, E., additional, Dogac, A., additional, Luepkes, C., additional, Ploessnig, M., additional, Chronaki, C., additional, Hinterbuchner, L., additional, Guillen, A., additional, Bun, S. S., additional, Latcu, D. G., additional, Franceschi, F., additional, Prevot, S., additional, Koutbi, L., additional, Ricard, P., additional, Saoudi, N., additional, Nazari, N., additional, Alizadeh, A., additional, Sayah, S., additional, Hekmat, M., additional, Assadian, M., additional, Ahmadzadeh, A., additional, Wnuk, M., additional, Jedrzejczyk-Spaho, J., additional, Kruszelnicka, O., additional, Piwowarska, W., additional, Fedorowski, A., additional, Burri, P., additional, Juul-Moller, S., additional, Melander, O., additional, Mitro, P., additional, Murin, P., additional, Kirsch, P., additional, Habalova, V., additional, Slaba, E., additional, Matyasova, E., additional, Barlow, M. A., additional, Blake, R. J., additional, Rostoff, P., additional, Wojewodka Zak, E., additional, Froidevaux, L., additional, Sarasin, F. P., additional, Louis-Simonet, M., additional, Hugli, O., additional, Yersin, B., additional, Schlaepfer, J., additional, Mischler, C., additional, Pruvot, E., additional, Occhetta, E., additional, Frascarelli, F., additional, Burali, A., additional, and Dovellini, E., additional
Published: 2011
Full Text: View/download PDF

8. Poster Session 2

Author: Andersson, T., primary, Magnusson, A., additional, Bryngelsson, I.- L., additional, Frobert, O., additional, Henriksson, K. M., additional, Edvardsson, N., additional, Poci, D., additional, Polovina, M., additional, Potpara, T., additional, Licina, M., additional, Mujovic, N., additional, Kocijancic, A., additional, Simic, D., additional, Ostojic, M. C., additional, Providencia, R. A., additional, Botelho, A., additional, Trigo, J., additional, Nascimento, J., additional, Quintal, N., additional, Mota, P., additional, Leitao-Marques, A. M., additional, Bosch, R. F., additional, Kirch, W., additional, Rosin, L., additional, Willich, S. N., additional, Pittrow, D., additional, Bonnemeier, H., additional, Valenza, M. C., additional, Martin, L., additional, Munoz Casaubon, T., additional, Valenza, G., additional, Botella, M., additional, Serrano, M., additional, Valenza, B., additional, Cabrera, I., additional, Anderson, K., additional, Benzaquen, B. S., additional, Koziolova, N., additional, Nikonova, J., additional, Shilova, Y., additional, Scherr, D., additional, Narayan, S., additional, Wright, M., additional, Krummen, D., additional, Jadidi, A., additional, Jais, P., additional, Haissaguerre, M., additional, Hocini, M., additional, Hunter, R., additional, Liu, Y., additional, Lu, Y., additional, Wang, W., additional, Schilling, R. J., additional, Bernstein, S., additional, Wong, B., additional, Rooke, R., additional, Vasquez, C., additional, Shah, R., additional, Rosenberg, S., additional, Chinitz, L., additional, Morley, G., additional, Bashir Choudhary, M., additional, Holmqvist, F., additional, Carlson, J., additional, Nilsson, H.- J., additional, Platonov, P. G., additional, Jadidi, A. S., additional, Cochet, H., additional, Miyazaki, S., additional, Shah, A. J., additional, Marrouche, N., additional, Calvo, N., additional, Nadal, M., additional, Andreu, D., additional, Tamborero, D., additional, Diaz, F. E., additional, Berruezo, A., additional, Brugada, J., additional, Mont, L., additional, Fichtner, S., additional, Hessling, G., additional, Estner, H. L., additional, Jilek, C., additional, Reents, T., additional, Ammar, S., additional, Wu, J., additional, Deisenhofer, I., additional, Nakanishi, H., additional, Kashiwase, K., additional, Hirata, A., additional, Wada, M., additional, Ueda, Y., additional, Skoda, J., additional, Neuzil, P., additional, Popelova, J., additional, Petru, J., additional, Sediva, L., additional, Reddy, V. Y., additional, Uldry, L., additional, Forclaz, A., additional, Virag, N., additional, Vesin, J.- M., additional, Kappenberger, L., additional, Sehra, R., additional, Briggs, C., additional, Rappel, W.- J., additional, Janotka, M., additional, Chovanec, M., additional, Yamashiro, K., additional, Takami, K., additional, Sakamoto, Y., additional, Satoh, K., additional, Suzuki, T., additional, Nakagawa, H., additional, Romanov, A., additional, Pokushalov, E., additional, Artemenko, S., additional, Shabanov, V., additional, Stenin, I., additional, Elesin, D., additional, Turov, A., additional, Yakubov, A., additional, Hioki, M., additional, Matsuo, S., additional, Ito, K., additional, Narui, R., additional, Yamashita, S., additional, Sugimoto, K., additional, Yoshimura, M., additional, Yamane, T., additional, Di Biase, L., additional, Gallinghouse, J. D., additional, Rajappan, K., additional, Kautzner, J., additional, Dello Russo, A., additional, Tondo, C., additional, Lorgat, F., additional, Natale, A., additional, Balta, O., additional, Buenz, K., additional, Paessler, M., additional, Anders, H., additional, Horlitz, M., additional, Deneke, T., additional, Lickfett, L., additional, Liberman, I., additional, Linhart, M., additional, Andrie, R., additional, Mittmann-Braun, E., additional, Stockigt, F., additional, Nickenig, G., additional, Schrickel, J., additional, Tilz, R., additional, Rillig, A., additional, Feige, B., additional, Metzner, A., additional, Fuernkranz, A., additional, Burchard, A., additional, Wissner, E., additional, Ouyang, F., additional, Betts, T. R., additional, Jones, M. A., additional, Wong, K. C. K., additional, Qureshi, N., additional, Bashir, Y., additional, Corbucci, G., additional, Losik, D., additional, Selina, V., additional, Crandall, M. A., additional, Daniels, C., additional, Daoud, E., additional, Kalbfleisch, S., additional, Yamaji, H., additional, Murakami, T., additional, Kawamura, H., additional, Murakami, M., additional, Hina, K., additional, Kusachi, S., additional, Dakos, G., additional, Vassilikos, V., additional, Paraskevaidis, S., additional, Mantziari, A., additional, Theophylogiannakos, S., additional, Chouvarda, I., additional, Chatzizisis, I., additional, Styliadis, I., additional, Kimura, T., additional, Fukumoto, K., additional, Nishiyama, N., additional, Aizawa, Y., additional, Fukuda, Y., additional, Sato, T., additional, Miyoshi, S., additional, Takatsuki, S., additional, Navarrete Casas, A. J., additional, Ali, I., additional, Conte, F. C., additional, Moran, M., additional, Graham, B. G., additional, Kalejs, O., additional, Lacis, R., additional, Stradins, P., additional, Koris, A., additional, Putnins, I., additional, Vikmane, M., additional, Lejnieks, A., additional, Erglis, A., additional, Estrada, A., additional, Perez Silva, A., additional, Castrejon, S., additional, Doiny, D., additional, Merino, J. L., additional, Baranchuk, A., additional, Greiss, I., additional, Simpson, C. S., additional, Abdollah, H., additional, Redfearn, D. P., additional, Buys-Topart, M., additional, Nitzsche, R., additional, Thibault, B., additional, Kathan, S., additional, Kolb, C., additional, Reif, S., additional, Schade, S., additional, Taggeselle, J., additional, Frey, A., additional, Birkenhagen, A., additional, Kohler, S., additional, Schmidt, M., additional, Cano Perez, O., additional, Buendia, F., additional, Igual, B., additional, Osca, J. M., additional, Sanchez, J. M., additional, Sancho-Tello, M. J., additional, Olague, J. M., additional, Salvador, A., additional, Tolosana, J. M., additional, Fernandez-Armenta, J., additional, Matas, M., additional, Barbarin, M. C., additional, Habibovic, M., additional, Van Den Broek, K. C., additional, Theuns, D. A. M. J., additional, Jordaens, L., additional, Alings, M., additional, Van Der Voort, P. H., additional, Pedersen, S. S., additional, Pupita, G., additional, Molini, S., additional, Brambatti, M., additional, Capucci, A., additional, Molodykh, S., additional, Idov, E. M., additional, Belyaev, O. V., additional, Segreti, L., additional, Soldati, E., additional, Zucchelli, G., additional, Di Cori, A., additional, Viani, S., additional, Paperini, L., additional, De Lucia, R., additional, Bongiorni, M. G., additional, Binner, L., additional, Taborsky, M., additional, Bello, D., additional, Heuer, H., additional, Ramza, B., additional, Jenniskens, I., additional, Johnson, W. B., additional, Silvetti, M. S., additional, Rava', L., additional, Russo, M. S., additional, Di Mambro, C., additional, Ammirati, A., additional, Gimigliano, G., additional, Prosperi, M., additional, Drago, F., additional, Santos, A. R., additional, Picarra, B., additional, Semedo, P., additional, Dionisio, P., additional, Matos, R., additional, Leitao, M., additional, Jacinto, A., additional, Trinca, M., additional, Mazzone, P., additional, Ciconte, G., additional, Marzi, A., additional, Paglino, G., additional, Vergara, P., additional, Sora, N., additional, Gulletta, S., additional, Della Bella, P., additional, Koppitz, P., additional, Fach, A., additional, Hobbiesiefken, S., additional, Fiehn, E., additional, Hambrecht, R., additional, Sperzel, J., additional, Jung, M., additional, Schmitt, J., additional, Pajitnev, D., additional, Burger, H., additional, Goebel, G., additional, Ehrlich, W., additional, Walther, T., additional, Ziegelhoeffer, T., additional, Vancura, V., additional, Wichterle, D., additional, Melenovsky, V., additional, Glikson, M., additional, Goldenberg, G., additional, Segev, A., additional, Dvir, D., additional, Kuzniec, J., additional, Finkelstein, A., additional, Hay, I., additional, Guetta, V., additional, Choo, W. K., additional, Gupta, S., additional, Kirkfeldt, R., additional, Johansen, J., additional, Nohr, E., additional, Moller, M., additional, Arnsbo, P., additional, Nielsen, J., additional, Banha, M., additional, Stojanov, P., additional, Raspopovic, S., additional, Vasic, D., additional, Savic, D., additional, Nikcevic, G., additional, Jovanovic, V., additional, Defaye, P., additional, Mondesert, B., additional, Mbaye, A., additional, Cassagneau, R., additional, Gagniere, V., additional, Jacon, J., additional, Sanfins, V., additional, Reis, H. R., additional, Nobre, J. N., additional, Martins, V. M., additional, Duarte, L. D., additional, Morais, C. M., additional, Conceicao, J. C., additional, Hero, M., additional, Rey, J. L., additional, Ducharme, A., additional, Simpson, C., additional, Stuglin, C., additional, Blier, L., additional, Senaratne, M., additional, Khaykin, Y., additional, Pinter, A., additional, Mlynarska, A., additional, Mlynarski, R., additional, Sosnowski, M., additional, Wilczek, J., additional, Iorgulescu, C., additional, Bogdan, S., additional, Constantinescu, D., additional, Caldararu, C., additional, Dorobantu, M., additional, Radu, A., additional, Vatasescu, R.- G., additional, Yusu, S., additional, Ikeda, T., additional, Mera, H., additional, Miwa, Y., additional, Abe, A., additional, Miyakoshi, M., additional, Tsukada, T., additional, Yoshino, H., additional, Nayar, V., additional, Cantelon, P., additional, Rawling, A., additional, Belham, M. R. D., additional, Pugh, P. J., additional, Osca Asensi, J., additional, Cano, O., additional, Tejada, D., additional, Munoz, B., additional, Rodriguez, M., additional, Olague, J., additional, Wecke, L., additional, Van Hunnik, A., additional, Thompson, T., additional, Di Carlo, L., additional, Zdeblick, M., additional, Auricchio, A., additional, Prinzen, F., additional, Doltra Magarolas, A., additional, Bijnens, B., additional, Silva, E., additional, Penela, D., additional, Sitges, M., additional, Ofman, P., additional, Navaravong, L., additional, Leng, J., additional, Peralta, A., additional, Hoffmeister, P., additional, Levine, R., additional, Cook, J., additional, Stoenescu, M., additional, Tettamanti, M. E., additional, Revilla Orodea, A., additional, Lopez Diaz, J., additional, De La Fuente Galan, L., additional, Arnold, R., additional, Garcia Moran, E., additional, San Roman Calvar, J. A., additional, Gomez Salvador, I., additional, Nakamura, K., additional, Takami, M., additional, Keida, T., additional, Mesato, A., additional, Higa, S., additional, Shimabukuro, M., additional, Masuzaki, H., additional, Proietti, R., additional, Sagone, A., additional, Domenichini, G., additional, Burri, H., additional, Valzania, C., additional, Biffi, M., additional, Sunthorn, H., additional, Gavaruzzi, G., additional, Foulkes, H., additional, Boriani, G., additional, Koh, S., additional, Hou, W., additional, Snell, J., additional, Poore, J., additional, Dalal, N., additional, Bornzin, G., additional, Kloppe, A., additional, Mijic, D., additional, Bogossian, H., additional, Ninios, I., additional, Zarse, M., additional, Lemke, B., additional, Guedon-Moreau, L., additional, Kouakam, C., additional, Klug, D., additional, Marquie, C., additional, Ziglio, F., additional, Kacet, S., additional, Mohamed Fereig Hamed, H., additional, Hamdy, A. M. A. L., additional, Abd El Aziz, A. H. M. E. D., additional, Nabih, M. R. V. A. T., additional, Hamdy, R. E. H. A. B., additional, Yaminisaharif, A., additional, Davoudi, G. H., additional, Kasemisaeid, A., additional, Sadeghian, S., additional, Vasheghani Farahani, A., additional, Yazdanifard, P., additional, Shafiee, A., additional, Alonso, C., additional, Grimard, C., additional, Jauvert, G., additional, Lazarus, A., additional, Mont, L. L., additional, Ortiz-Perez, J., additional, Caralt, T., additional, Escudero, J., additional, Perez, F., additional, Griffith, K. M., additional, Ferreyra, R., additional, Urena, P., additional, Demas, M., additional, Muratore, C., additional, Mazzetti, H., additional, Guardado, J., additional, Fernandes, M., additional, Pereira, V. H., additional, Canario-Almeida, F., additional, Ferreira, F., additional, Rodrigues, B., additional, Almeida, J., additional, Sokal, A., additional, Jedrzejczyk, E., additional, Lenarczyk, R., additional, Pluta, S., additional, Kowalski, O., additional, Pruszkowska, P., additional, Swiatkowski, A., additional, Kalarus, Z., additional, Heinke, M., additional, Ismer, B., additional, Kuehnert, H., additional, Heinke, T., additional, Surber, R., additional, Osypka, N., additional, Prochnau, D., additional, Figulla, H. R., additional, Iacopino, S., additional, Landolina, M., additional, Proclemer, A., additional, Padeletti, L., additional, Calvi, V., additional, Pierantozzi, A., additional, Di Stefano, P., additional, Bauer, A., additional, Bode, F., additional, Le Gal, F., additional, Deharo, J. C., additional, Delay, M., additional, Clementy, J., additional, Kawamura, M., additional, Munetsugu, Y., additional, Tanno, K., additional, Kobayashi, Y., additional, Cannom, D., additional, Hosoda, J., additional, Ishikawa, T., additional, Andoh, K., additional, Nobuyoshi, M., additional, Fujii, S., additional, Shizuta, S., additional, Isshiki, T., additional, Castel, M. A., additional, Perez-Villa, F., additional, Vidal, B., additional, Pruszkowska-Skrzep, P., additional, Szulik, M., additional, Kukulski, T., additional, Gianfranchi, L., additional, Bettiol, K., additional, Pacchioni, F., additional, Alboni, P., additional, Abu Sham'a, R., additional, Buber, J., additional, Nof, E., additional, Kuperstein, R., additional, Feinberg, M., additional, Luria, D., additional, Eldar, M., additional, Parks, K., additional, Stone, J. R., additional, Singh, J. P., additional, Hatzinikolaou-Kotsakou, E., additional, Kotsakou, M., additional, Beleveslis, T. H., additional, Moschos, G., additional, Reppas, E., additional, Latsios, P., additional, Tsakiridis, K., additional, Kazemisaeid, A., additional, Davoodi, G., additional, Yamini Sharif, A., additional, Sheikhvatan, M., additional, Toniolo, M., additional, Zanotto, G., additional, Rossi, A., additional, Tomasi, L., additional, Vassanelli, C., additional, Versteeg, H., additional, Mommersteeg, P. M. C., additional, Vergara, G., additional, Blauer, J., additional, Ranjan, R., additional, Vijayakumar, S., additional, Kholmovski, E., additional, Volland, N., additional, Macleod, R., additional, Aguinaga Arrascue, L. E., additional, Bravo, A., additional, Garcia Freire, P., additional, Gallardo, P., additional, Hasbani, E., additional, Dantur, J., additional, Quintana, R., additional, Adragao, P. P., additional, Cavaco, D., additional, Parreira, L., additional, Reis Santos, K., additional, Carmo, P., additional, Miranda, R., additional, Marcelino, S., additional, Cabrita, D., additional, Sommer, P., additional, Gaspar, T., additional, Rolf, S., additional, Arya, A., additional, Piorkowski, C., additional, Hindricks, G., additional, Valles Gras, E., additional, Bazan, V., additional, Portillo, L., additional, Suarez, F., additional, Bruguera, J., additional, Marti, J., additional, Huo, Y., additional, Richter, S., additional, Schoenbauer, R., additional, Rivas, N., additional, Casaldaliga, J., additional, Roca, I., additional, Dos, L., additional, Perez-Rodon, J., additional, Pijuan, A., additional, Garcia-Dorado, D., additional, Moya, A., additional, Carter, H. B., additional, Garg, A., additional, Hegrenes, J., additional, Sih, H. J., additional, Teplitsky, L. R., additional, Kuroki, K., additional, Tada, H., additional, Seo, Y., additional, Ishizu, T., additional, Igawa, M., additional, Sekiguchi, Y., additional, Kuga, K., additional, Aonuma, K., additional, Rodriguez A, C., additional, Mejias, J., additional, Hidalgo, P., additional, Hidalgo L, J. A., additional, Orczykowski, M., additional, Derejko, P., additional, Walczak, F., additional, Szufladowicz, E., additional, Urbanek, P., additional, Bodalski, R., additional, Bieganowska, K., additional, Szumowski, L., additional, Peichl, P., additional, Cihak, R., additional, Skalsky, I., additional, Kubus, P., additional, Vit, P., additional, Zaoral, L., additional, Gebauer, R. A., additional, Fiala, M., additional, Janousek, J., additional, Hiroshima, K., additional, Goya, M., additional, Ohe, M., additional, Hayashi, K., additional, Makihara, Y., additional, Nagashima, M., additional, An, Y., additional, Schloesser, M., additional, Lawrenz, T., additional, Meyer Zu Vilsendorf, D., additional, Strunk-Mueller, C., additional, Stellbrink, C., additional, Papagiannis, J., additional, Avramidis, D., additional, Kokkinakis, C., additional, Kirvassilis, G., additional, Eidelman, G., additional, Arenal, A., additional, Datino, T., additional, Atienza, F., additional, Gonzalez Torrecilla, E., additional, Miracle, A., additional, Hernandez, J., additional, Fernandez Aviles, F., additional, Ene, E., additional, Insulander, P., additional, Bastani, H., additional, Braunschweig, F., additional, Drca, N., additional, Kenneback, G., additional, Schwieler, J., additional, Tapanainen, J., additional, Jensen-Urstad, M., additional, Andrea, B., additional, Andrea, E. M. A., additional, Maciel, W. M., additional, Siqueira, L. S., additional, Cosenza, R. C., additional, Mittidieri, F. M., additional, Farah, S. F., additional, Atie, J. A., additional, Kanoupakis, E., additional, Kallergis, E., additional, Mavrakis, H., additional, Goudis, C., additional, Saloustros, I., additional, Malliaraki, N., additional, Chlouverakis, G., additional, Vardas, P., additional, Bonnes, J. L., additional, Jaspers Focks, J., additional, Westra, S. W., additional, Brouwer, M. A., additional, Smeets, J. L. R. M., additional, Inama, G., additional, Pedrinazzi, C., additional, Oliva, F., additional, Senni, M., additional, Zoni Berisso, M., additional, Mostov, S., additional, Haim, M., additional, Nevzorov, R., additional, Hasadi, D., additional, Starsberg, B., additional, Porter, A., additional, Kuschyk, J., additional, Schoene, A., additional, Streitner, F., additional, Veltmann, C. G., additional, Schimpf, R., additional, Borggrefe, M., additional, Luesebrink, U., additional, Gardiwal, A., additional, Oswald, H., additional, Koenig, T., additional, Duncker, D., additional, Klein, G., additional, Bastiaenen, R., additional, Batchvarov, V., additional, Atty, O., additional, Cheng, J. H., additional, Behr, E. R., additional, Gallagher, M. M., additional, Starrenburg, A. H., additional, Kraaier, K., additional, Scholten, M. F., additional, Van Der Palen, J., additional, Adhya, S., additional, Smith, L. A., additional, Zhao, T., additional, Bannister, C., additional, Kamdar, R. H., additional, Martinelli, M., additional, Siqueira, S., additional, Greco, R., additional, Nishioka, S. A. D., additional, Pedrosa, A. A. A., additional, Alkmim-Teixeira, R., additional, Peixoto, G. L., additional, Costa, R., additional, Nielsen, J. C., additional, Mortensen, P. T., additional, Johansen, J. B., additional, Kwasniewski, W., additional, Filipecki, A., additional, Urbanczyk-Swic, D., additional, Orszulak, W., additional, Trusz - Gluza, M., additional, Jimenez-Candil, J., additional, Morinigo, J., additional, Ledesma, C., additional, Martin-Luengo, C., additional, Vogtmann, T., additional, Gomer, M., additional, Stiller, S., additional, Kuehlkamp, V., additional, Zach, G., additional, Loescher, S., additional, Kespohl, S., additional, Baumann, G., additional, Snell, J. D., additional, Korsun, N., additional, Snell, J. R., additional, Morley, B., additional, Bharmi, R., additional, Nabutovsky, Y., additional, Mollerus, M., additional, Naslund, L., additional, Meyer, A., additional, Lipinski, M., additional, Libey, B., additional, Dornfeld, K., additional, Martin, A., additional, Gallego, M., additional, De Bie, M. K., additional, Van Rees, J. B., additional, Borleffs, C. J., additional, Thijssen, J., additional, Jukema, J. W., additional, Schalij, M. J., additional, Van Erven, L., additional, Van Der Velde, E. T., additional, Witteman, T. A., additional, Foeken, H., additional, Szili-Torok, T., additional, Akca, F., additional, Caliskan, K., additional, Ten Cate, F., additional, Michels, M., additional, Cozma, D. C., additional, Petrescu, L., additional, Mornos, C., additional, Dragulescu, S. I., additional, Groeneweg, J. A., additional, Velthuis, B. K., additional, Cox, M. G. P. J., additional, Loh, P., additional, Dooijes, D., additional, Cramer, M. J., additional, De Bakker, J. M. T., additional, Hauer, R. N. W., additional, Park, S. D., additional, Shin, S. H., additional, Woo, S. I., additional, Kwan, J., additional, Park, K. S., additional, Kim, D. H., additional, Iorio, A., additional, Vitali Serdoz, L., additional, Brun, F., additional, Daleffe, E., additional, Zecchin, M., additional, Dal Ferro, M., additional, Santangelo, S., additional, Sinagra, G. F., additional, Ouali, S., additional, Hammemi, R., additional, Hammas, S., additional, Kacem, S., additional, Gribaa, R., additional, Neffeti, E., additional, Remedi, F., additional, Boughzela, E., additional, Korantzopoulos, P., additional, Letsas, K., additional, Christogiannis, Z., additional, Kalantzi, K., additional, Ntorkos, A., additional, Goudevenos, J., additional, Foley, P. W. X., additional, Yung, L., additional, Barnes, E., additional, Kikuchi, M., additional, Ito, H., additional, Miyoshi, F., additional, Pecini, R., additional, Marott, J. M., additional, Jensen, G. B., additional, Theilade, J., additional, Mine, T., additional, Kodani, T., additional, Masuyama, T., additional, Mozos, I. M., additional, Serban, C., additional, Costea, C., additional, Susan, L., additional, Barthel, P., additional, Mueller, A., additional, Malik, M., additional, Schmidt, G., additional, Karakurt, O., additional, Kilic, H., additional, Munevver Sari, D. R., additional, Mroczek-Czernecka, D., additional, Pietrucha, A. Z., additional, Borowiec, A., additional, Wnuk, M., additional, Bzukala, I., additional, Kruszelnicka, O., additional, Konduracka, E., additional, Nessler, J., additional, Kikuchi, Y., additional, Meireles, A., additional, Gomes, C., additional, Anjo, D., additional, Roque, C., additional, Pinheiro Vieira, A., additional, Lagarto, V., additional, Hipolito Reis, A., additional, Torres, S., additional, Miller, L., additional, Vedrenne, G., additional, Bruguiere, E., additional, Redheuil, A., additional, Lavergne, T., additional, Le Heuzey, J. Y., additional, Mousseaux, E., additional, Hersi, A., additional, Alhabib, K., additional, Alfaleh, H., additional, Sulaiman, K., additional, Almahmeed, W., additional, Alsuwidi, J., additional, Amin, H., additional, Almotarreb, A., additional, Pang, H. W. K., additional, Michael, K., additional, Pereira, E. J., additional, Munt, P. W., additional, Fitzpatrick, M. F., additional, Revishvili, A. S., additional, Simonyan, G., additional, Dzhordzhikiya, T., additional, Sopov, O., additional, Kalinin, V., additional, Locati, E. T., additional, Vecchi, A. M., additional, Cattafi, G., additional, Sachero, A., additional, Lunati, M., additional, Sayah, S., additional, Alizadeh, A., additional, Nazari, N., additional, Hekmat, M., additional, Moradi, M., additional, Zeighami, M., additional, Ghanji, H., additional, Suzuki, K., additional, Takagi, M., additional, Maeda, K., additional, Tatsumi, H., additional, Vieira, P., additional, Reis, H., additional, Toth, A., additional, Vago, H., additional, Takacs, P., additional, Edes, E., additional, Marki, A., additional, Balazs, G. Y., additional, Huttl, K., additional, Merkely, B., additional, Lainis, F., additional, Buckley, M. M., additional, Johns, E. J., additional, Seifer, C. M., additional, Daba, L., additional, Liebrecht, K., additional, Piwowarska, W., additional, Toquero Ramos, J., additional, Perez Pereira, E., additional, Mitroi, C., additional, Castro Urda, V., additional, Fernandez Villanueva, J. M., additional, Corona Figueroa, A., additional, Hernandez Reina, L., additional, Fernandez Lozano, I., additional, Bartoletti, A., additional, Bocconcelli, P., additional, Giuli, S., additional, Massa, R., additional, Svetlich, C., additional, Tarsi, G., additional, Tronconi, F., additional, Vitale, E., additional, Stryjewski, P., additional, Wegrzynowska, M., additional, Lousinha, A., additional, Labandeiro, J., additional, Antunes, E., additional, Silva, S., additional, Alves, S., additional, Timoteo, A., additional, Oliveira, M., additional, Cruz Ferreira, R., additional, and Jedrzejczyk-Spaho, J., additional
Published: 2011
Full Text: View/download PDF

9. Prevalence of interatrial block in a general population of elderly people.

Author: Ninios I, Pliakos C, Ninios V, Karvounis H, Louridas G, Ninios, Ilias, Pliakos, Christodoulos, Ninios, Vlasios, Karvounis, Haralampos, and Louridas, George
Abstract: Background: Interatrial block (IAB: P wave > or = 110 ms) is highly prevalent in people > or =65 years old living in a community.Methods: We investigated 720 consecutive people age > or =65 years old, from the general population, with the intention of evaluating the prevalence of IAB in their electrocardiogram. After excluding 42 people with atrial fibrillation and atrial flutter (5%) or having a permanent pacemaker (0,83%), we evaluated the electrocardiograms of the remaining 678 people with sinus rhythm.Results: We identified 400 (59%) persons with IAB with a similar distribution between men (58.5%) and women (59.4%). IAB was also identified in 347 from a total of 570 hypertensive people (60,9%) and only in 53 out of 108 (49.1%) nonhypertensive people (P = 0.015).Conclusions: The surprisingly large prevalence of the IAB in the general older population emphasizes the importance of the early recognition of this abnormality from the surface 12-lead electrocardiogram. [ABSTRACT FROM AUTHOR]
Published: 2007

10. Safety and Efficacy in Mitral Regurgitation Management with the MitraClip ® G4 System: Insights from a Single-Center Study.

Author: Papadopoulos GE, Ninios I, Evangelou S, Ioannidis A, and Ninios V
Abstract: Background: Mitral regurgitation (MR) is a common valvular disorder linked to high morbidity and mortality. For patients unsuitable for surgery, transcatheter mitral edge-to-edge repair (TEER) with the MitraClip ® G4 system offers an alternative. This study aims to evaluate procedural, echocardiographic, functional, and quality of life (QoL) outcomes in patients who underwent TEER with the MitraClip ® G4 system, along with possible predictors of New York Heart Association (NYHA) class I at 30 days and at 1 year., Methods: Patients with moderate-to-severe (3+) or severe (4+) degenerative MR (DMR) or functional MR (FMR), classified as NYHA class III or IV, and who underwent TEER with the MitraClip ® G4 system at our center between January 2021 and December 2023 were included., Results: A total of 83 patients [71% FMR, 66% male, median (IQR) age 70 (11) years] underwent TEER, with 100% procedural success. MR ≤ 2+ was achieved in 100% and 98% of patients at 30 days and 1 year, respectively. NYHA class I or II was achieved in 100% and 96.8% of patients at 30 days and 1 year, respectively. The Kansas City Cardiomyopathy Questionnaire (KCCQ) score improved from 51 ± 20 at baseline to 69 ± 15 at 30 days ( p < 0.001) and 70.5 ± 15 at 1 year ( p < 0.001). Lower baseline N-terminal pro-brain natriuretic peptide (NT-proBNP) predicted achieving NYHA class I at 30 days (HR: 0.63, 95% CI: 0.41-0.95, p = 0.030), while lower European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) and NT-proBNP predicted it at 1 year [(HR: 0.50, 95% CI: 0.28-0.89, p = 0.019), (HR: 0.67, 95% CI: 0.44-0.99, p = 0.049), respectively]., Conclusions: The MitraClip ® G4 system provides significant improvements in MR severity, functional class, and QoL. Lower NT-proBNP and EuroSCORE II were strong predictors of achieving optimal functional status (NYHA class I).
Published: 2024
Full Text: View/download PDF

11. Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2.

Author: Ponikowski P, Friede T, von Bardeleben RS, Butler J, Shahzeb Khan M, Diek M, Heinrich J, Geyer M, Placzek M, Ferrari R, Abraham WT, Alfieri O, Auricchio A, Bayes-Genis A, Cleland JGF, Filippatos G, Gustafsson F, Haverkamp W, Kelm M, Kuck KH, Landmesser U, Maggioni AP, Metra M, Ninios V, Petrie MC, Rassaf T, Ruschitzka F, Schäfer U, Schulze PC, Spargias K, Vahanian A, Zamorano JL, Zeiher A, Karakas M, Koehler F, Lainscak M, Öner A, Mezilis N, Theofilogiannakos EK, Ninios I, Chrissoheris M, Kourkoveli P, Papadopoulos K, Smolka G, Wojakowski W, Reczuch K, Pinto FJ, Wiewiórka Ł, Streb W, Adamo M, Santiago-Vacas E, Friedrich Ruf T, Gross M, Tongers J, Hasenfuß G, Schillinger W, and Anker SD
Subjects: Humans, Male, Female, Aged, Severity of Illness Index, Aged, 80 and over, Cardiac Catheterization methods, Treatment Outcome, Heart Valve Prosthesis Implantation instrumentation, Heart Valve Prosthesis Implantation methods, Heart Valve Prosthesis Implantation trends, Mitral Valve Insufficiency surgery, Heart Failure therapy, Heart Failure mortality, Heart Failure surgery, Hospitalization statistics & numerical data, Hospitalization trends
Abstract: Background: For patients with functional mitral regurgitation (FMR) and symptomatic heart failure (HF), randomized trials of mitral transcatheter edge-to-edge repair (M-TEER) have produced conflicting results., Objectives: This study sought to assess the impact of M-TEER on hospitalization rates, and explore the effects of M-TEER on patients who did or did not have a history of recent HF hospitalizations before undergoing M-TEER., Methods: RESHAPE-HF2 (Randomized Investigation of the MitraClip Device in Heart Failure: 2nd Trial in Patients with Clinically Significant Functional Mitral Regurgitation) included patients with symptomatic HF and moderate to severe FMR (mean effective regurgitant orifice area 0.25 cm 2 ; 14% >0.40 cm 2 , 23% <0.20 cm 2 ) and showed that M-TEER reduced recurrent HF hospitalizations with and without the addition of cardiovascular (CV) death and improved quality of life. We now report the results of prespecified analyses on hospitalization rates and for the subgroup of patients (n = 333) with a HF hospitalization in the 12 months before randomization., Results: At 24 months, the time to first event of CV death or HF hospitalization (HR: 0.65; 95% CI: 0.49-0.85; P = 0.002), the rate of recurrent CV hospitalizations (rate ratio [RR]: 0.75; 95% CI: 0.57-0.99; P = 0.046), the composite rate of recurrent CV hospitalizations and all-cause mortality (RR: 0.74; 95% CI: 0.57-0.95; P = 0.017), and of recurrent CV death and CV hospitalizations (RR: 0.76; 95% CI: 0.58-0.99; P = 0.040), were all lower in the M-TEER group. The RR of recurrent hospitalizations for any cause was 0.82 (95% CI: 0.63-1.07; P = 0.15) for patients in the M-TEER group vs control group patients. Patients randomized to M-TEER lost fewer days due to death or HF hospitalization (13.9% [95% CI: 13.0%-14.8%] vs 17.4% [95% CI: 16.4%-18.4%] of follow-up time; P < 0.0001, and 1,067 vs 1,776 total days lost; P < 0.0001). Patients randomized to M-TEER also had better NYHA functional class at 30 days and at 6, 12, and 24 months of follow-up (P < 0.0001). A history of HF hospitalizations before randomization was associated with worse outcomes and greater benefit with M-TEER on the rate of the composite of recurrent HF hospitalizations and CV death (P interaction = 0.03) and of recurrent HF hospitalizations within 24 months (P interaction = 0.06)., Conclusions: These results indicate that a broader application of M-TEER in addition to optimal guideline-directed medical therapy should be considered among patients with symptomatic HF and moderate to severe FMR, particularly in those with a history of a recent hospitalization for HF., Competing Interests: Funding Support and Author Disclosures Prof Ponikowski has received a grant from Vifor Pharma; has received consulting fees and/or honoraria from Boehringer Ingelheim, AstraZeneca, Vifor Pharma, Servier, Novartis, Berlin Chemie, Bayer, Abbott Vascular, Novo Nordisk, Pharmacosmos, Moderna, Pfizer, and Abbott Vascular; and has received fees for trial committee work from Boehringer Ingelheim, Vifor Pharma, Novo Nordisk, Pharmacosmos, and Moderna. Dr Friede has received payments to his institution from Abbott; has received grants from Deutsche Forschungsgemeinschaft (DFG), Federal Joint Committee (G-BA), and European Commission; has received consulting fees from Actimed, Bayer, BMS, CSL Behring, Daiichi-Sankyo, Galapagos, Immunic, KyowaKirin, LivaNova, Minoryx, Novartis, RECARDIO, Relaxera, Roche, Servier, Viatris, and Vifor; has received payments from Fresenius Kabi and PINK gegen Brustkrebs; is a trial data monitoring committee member for Aslan, Bayer, Biosense Webster, Enanta, Galapagos, IQVIA, Novartis, PPD, Recordati, Roche, and VICO Therapeutics; and is a trial steering committee member for CSL Behring. Dr von Bardeleben has received an EchoCoreLab IIT grant from Clinical Trial Unit of UMG Göttingen; has received consulting fees from Abbott Vascular, Jenscare, Edwards Lifesciences, and Medtronic; has received honoraria from Abbott Vascular, Jenavalve, Jenscare, Edwards Lifesciences, Medtronic, Philips, Siemens; and is a trial committee member for Medtronic and Heart Valve Society (unpaid), and EU SHD Coalition (unpaid). Dr Butler has received consulting fees from Abbott, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, Cardiorem, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards Lifesciences, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Lexicon, Lilly, LivaNova, Janssen, Medtronic, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Pfizer, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, and Zoll; and has received honoraria from Novartis, Boehringer Ingelheim-Lilly, AstraZeneca, Impulse Dynamics, and Vifor. Dr Khan has participated in a data safety monitoring board or advisory board for Bayer. Dr Ferrari has received honoraria and support for attending meetings from Servier, Merck Serono, Bayer, Lupin, and Sunpharma. Dr Abraham has received payments from Abbott; has received grants from National Institutes of Health 1 UG3 / UH3 HL140144-01; has received consulting fees from Zoll Respicardia; has received honoraria from Impulse Dynamics, Edwards Lifesciences, and Abbott; and is an advisory board member for Sensible Medical, WhiteSwell, AquaPass, Cordio Medical, and Boehringer Ingelheim. Dr Auricchio has received consulting fees and honoraria from Boston Scientific, Medtronic, Microport CRM, Philips, Xspline, and Abbott. Dr Bayes-Genis has lectured and/or participated in advisory boards for Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Medtronic, Novartis, Novo Nordisk, Roche Diagnostics, and Vifor. Dr Cleland has received grants from Bristol Myers Squibb, CSL-Vifor, British Heart Foundation, and Pharmacosmos; has received consulting fees from Pharmacosmos, CSL-Vifor, and Biopeutics; and has received honoraria from Pharmacosmos. Dr Filippatos has received honoraria from Bayer, Boehringer Ingelheim, Servier, and Novartis; has served on the trial committee boards for Bayer, Medtronic, Boehringer Ingelheim, Vifor, Amgen, Servier, Impulse Dynamics, Cardior, and Novo Nordisk; and has served on the boards of the Heart Failure Association and JACC Heart Failure. Dr Gustafsson has received consulting fees and/or honoraria from Abbott, Bayer, Pfizer, and AstraZeneca; has participated on the trial committee board of AdJuCor; and has served on the board of the Heart Failure Association. Dr Haverkamp has received consulting fees and/or honoraria from Bayer and AstraZeneca. Dr Kelm has received grants or contracts from Microvision Medical Holding B.V., Edwards Lifesciences, Mars Scientific Advisory Council, Abiomed Europe GmbH, B. Braun Melsungen AG, DFG SFB 1116, EU Horizon 2020, and Daiichi-Sankyo Deutschland GmbH; and has received payment or honoraria from Bayer Vital GmbH, Abiomed Europe GmbH, AstraZeneca, Amarin GmbH, and CTI congress GmbH. Dr Landmesser has received grants from Abbott and Novartis; and has received consulting fees and honoraria from Abbott. Dr Maggioni has participated on trial committee boards for Bayer, AstraZeneca, Novartis, and Sanofi. Dr Metra has received consulting fees from Abbott Structural Heart, Boehringer Ingelheim, AstraZeneca, Roche Diagnostics, Edwards Lifesciences, Novo Nordisk, and Bayer. Dr Petrie has received grants from Boehringer Ingelheim, Roche Diagnostics, SQ Innovations, AstraZeneca, Novartis, Novo Nordisk, Medtronic, Boston Scientific, and Pharmacosmos; has received consulting fees and/or honoraria from Akero, Applied Therapeutics, Amgen, AnaCardio, Biosensors, Boehringer Ingelheim, Corteria, FIRE-1, Biosensors, REPRIEVE, Corvia, Novartis, AstraZeneca, Novo Nordisk, AbbVie, Bayer, Horizon Therapeutics, Takeda, Cardiorentis, Pharmacosmos, Roche Pharma, Siemens, Eli Lilly, Vifor, New Amsterdam, Moderna, Teikoku, LIB Therapeutics, and 3R Lifesciences; and has participated on a data safety monitoring board or advisory board for AstraZeneca, Moderna, and Teikoku. Dr Rassaf has received consulting fees and/or honoraria from BMS, AstraZeneca, Pfizer, Novartis, Bayer, Daiichi-Sankyo, and CVRxInc; and has pending patent applications regarding amelioration and treatment of infarct damage (W02023079141A2), blood pressure lowering composition (EP3646861A1), and Bnip3 peptides for the treatment of reperfusion injury (C=2021015130A2). Dr Ruschitzka has not received personal payments by pharmaceutical companies or device manufacturers in the last 3 years; the Department of Cardiology (University Hospital of Zurich/University of Zurich); has received research, educational, and/or travel grants from Abbott, Abiomed, Alexion, Amgen, AstraZeneca, At the Limits Ltd Bayer, Berlin Heart, B. Braun, Biosense Webster, Biosensors Europe AG, Biotronik, BMS, Boehringer Ingelheim, Boston Scientific, Bracco, Cardinal Health Switzerland, Concept Medical, Corteria, CSL, Daiichi-Sankyo, Diatools AG, Edwards Lifesciences, Guidant Europe NV (BS), Hamilton Health Sciences, IHF, Innosuisse, Johnson/Johnson, Kaneka Corporation, Kantar, Kiniksa, Labormedizinisches Zentrum, MedAlliance, Medical Education Global Solutions, Medtronic, MicroPort, MSD, Mundipharma Medical Company, Novartis, Novo Nordisk, Orion, Pfizer, Quintiles Switzerland Sarl, Recor Medical, Roche Diagnostics, Roche Pharma, Sahajanand IN, Sanofi, Sarstedt AG, Servier, SIS Medical, Sorin CRM SAS, SSS International Clinical Research, Stromal, Terumo Deutschland, Trama Solutions, V-Wave, Vascular Medical, Vifor, Wissens Plus, and ZOLL. Dr Schäfer has received grants, consulting fees, honoraria, and personal fees for consultancies, trial committee work, and/or lectures from Abbott Vascular, Edwards Lifesciences, and Polares Medical. Dr Schulze has received grants from Boehringer Ingelheim, Abiomed Inc, Edwards Lifesciences Inc, Cytosorb Inc, and Boston Scientific; and has received consulting fees and/or honoraria from Bayer, AstraZeneca, Daiichi-Sankyo, Novartis, Actelion, Roche, Sanofi, Pharmacosmos, Medtronic, Thoratec, Boehringer Ingelheim, HeartWare, Coronus, Abbott, Boston Scientific, St. Jude Medical, Abiomed, and DGK, and trial committee work for Abbott, Abiomed. Dr Spargias has received fees for proctoring for Abbott Vascular. Dr Vahanian has participated on a data safety monitoring board for Edwards Lifesciences, VenusTech, and Mayo Clinic. Dr Zamorano has received personal payments or honoraria from Viatris, Bayer, and Novartis. Dr Zeiher has received grants or contracts from or served on scientific advisory boards for AstraZeneca, Boehringer Ingelheim, and Novo Nordisk. Dr Koehler has received grants for Project 5G-MedCamp from the German Federal Ministry of Economics and climate protection (BMWK) and grants for projects RESKRIVER and 6 G Health; and has received consulting fees and/or payments or honoraria from BIOTRONIK, Boehringer Ingelheim, Sanofi Germany GmbH, Novartis Germany (till 2022), and AMGEN Germany (in 2021). Dr Lainscak has received a grant from Slovenian Research Agency; and has received honoraria from Novartis, Boehringer Ingelheim, and AstraZeneca. Drs Mezilis and Theofilogiannakos have received support from Abbott for attending meetings. Dr Chrissoheris has received fees for proctoring from Abbott Vascular and Edwards Lifesciences; and has received honoraria from Edwards Lifesciences. Dr Papadopoulos has received consulting fees and honoraria from GE Healthcare. Dr Smolka has received fees for proctoring for Abbott Vascular. Dr Wojakowski has received consulting fees and/or honoraria from Abbott Vascular, Medtronic, and Edwards Lifesciences. Dr Reczuch has received honoraria for lectures from Abbott. Dr Pinto has received consulting fees and/or honoraria from Boehringer Ingelheim, Daichi-Sankyo, Novartis, Servier, Vifor, and Zydus; and participated on advisory boards for Medtronic, Novartis, Servier, and Vifor. Dr Adamo has received honoraria from Abbott Vascular and Edwards Lifesciences. Dr Ruf has received fees for proctoring and consulting from Abbott Laboratories and Edwards Lifesciences. Dr Hasenfuß has received personal fees from AstraZeneca, Boehringer, Corvia, Impulse Dynamics, Novartis, Pfizer, and Servier; and has served on trial committees for AstraZeneca, Boehringer, Corvia (no honoraria), Impulse Dynamics, Novartis, Servier, and Vifor Pharma. Dr Schillinger has received consulting and lecture fees and travel expenses from Abbott Vascular. Dr Anker has received grants and personal fees from Vifor and Abbott Vascular; has received personal fees for consultancies, trial committee work, and/or lectures from Actimed, AstraZeneca, Bayer, Bioventrix, Boehringer Ingelheim, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards Lifesciences, Farraday Pharmaceuticals, GSK, HeartKinetics, Impulse Dynamics, Medtronic, Novartis, Novo Nordisk, Occlutech, Pfizer, Regeneron, Relaxera, Repairon, Scirent, Sensible Medical, Servier, Vectorious, and V-Wave; and is named as coinventor of two patent applications regarding MR-proANP (DE 102007010834 & DE 102007022367), but he does not benefit personally from the related issued patents. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

12. Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation.

Author: Anker SD, Friede T, von Bardeleben RS, Butler J, Khan MS, Diek M, Heinrich J, Geyer M, Placzek M, Ferrari R, Abraham WT, Alfieri O, Auricchio A, Bayes-Genis A, Cleland JGF, Filippatos G, Gustafsson F, Haverkamp W, Kelm M, Kuck KH, Landmesser U, Maggioni AP, Metra M, Ninios V, Petrie MC, Rassaf T, Ruschitzka F, Schäfer U, Schulze PC, Spargias K, Vahanian A, Zamorano JL, Zeiher A, Karakas M, Koehler F, Lainscak M, Öner A, Mezilis N, Theofilogiannakos EK, Ninios I, Chrissoheris M, Kourkoveli P, Papadopoulos K, Smolka G, Wojakowski W, Reczuch K, Pinto FJ, Wiewiórka Ł, Kalarus Z, Adamo M, Santiago-Vacas E, Ruf TF, Gross M, Tongers J, Hasenfuss G, Schillinger W, and Ponikowski P
Subjects: Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Combined Modality Therapy, Kaplan-Meier Estimate, Severity of Illness Index, Recurrence, Cardiac Catheterization adverse effects, Cardiac Catheterization instrumentation, Cardiac Catheterization methods, Heart Failure complications, Heart Failure diagnosis, Heart Failure mortality, Heart Failure therapy, Hospitalization statistics & numerical data, Mitral Valve surgery, Mitral Valve Insufficiency diagnosis, Mitral Valve Insufficiency etiology, Mitral Valve Insufficiency mortality, Mitral Valve Insufficiency therapy
Abstract: Background: Whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation is uncertain., Methods: We conducted a randomized, controlled trial involving patients with heart failure and moderate to severe functional mitral regurgitation from 30 sites in nine countries. The patients were assigned in a 1:1 ratio to either transcatheter mitral-valve repair and guideline-recommended medical therapy (device group) or medical therapy alone (control group). The three primary end points were the rate of the composite of first or recurrent hospitalization for heart failure or cardiovascular death during 24 months; the rate of first or recurrent hospitalization for heart failure during 24 months; and the change from baseline to 12 months in the score on the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS; scores range from 0 to 100, with higher scores indicating better health status)., Results: A total of 505 patients underwent randomization: 250 were assigned to the device group and 255 to the control group. At 24 months, the rate of first or recurrent hospitalization for heart failure or cardiovascular death was 37.0 events per 100 patient-years in the device group and 58.9 events per 100 patient-years in the control group (rate ratio, 0.64; 95% confidence interval [CI], 0.48 to 0.85; P = 0.002). The rate of first or recurrent hospitalization for heart failure was 26.9 events per 100 patient-years in the device group and 46.6 events per 100 patient-years in the control group (rate ratio, 0.59; 95% CI, 0.42 to 0.82; P = 0.002). The KCCQ-OS score increased by a mean (±SD) of 21.6±26.9 points in the device group and 8.0±24.5 points in the control group (mean difference, 10.9 points; 95% CI, 6.8 to 15.0; P<0.001). Device-specific safety events occurred in 4 patients (1.6%)., Conclusions: Among patients with heart failure with moderate to severe functional mitral regurgitation who received medical therapy, the addition of transcatheter mitral-valve repair led to a lower rate of first or recurrent hospitalization for heart failure or cardiovascular death and a lower rate of first or recurrent hospitalization for heart failure at 24 months and better health status at 12 months than medical therapy alone. (Funded by Abbott Laboratories; RESHAPE-HF2 ClinicalTrials.gov number, NCT02444338.)., (Copyright © 2024 Massachusetts Medical Society.)
Published: 2024
Full Text: View/download PDF

13. Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials.

Author: Anker SD, Friede T, von Bardeleben RS, Butler J, Khan MS, Diek M, Heinrich J, Geyer M, Placzek M, Ferrari R, Abraham WT, Alfieri O, Auricchio A, Bayes-Genis A, Cleland JGF, Filippatos G, Gustafsson F, Haverkamp W, Kelm M, Kuck KH, Landmesser U, Maggioni AP, Metra M, Ninios V, Petrie MC, Rassaf T, Ruschitzka F, Schäfer U, Schulze PC, Spargias K, Vahanian A, Zamorano JL, Zeiher A, Karakas M, Koehler F, Lainscak M, Öner A, Mezilis N, Theofilogiannakos EK, Ninios I, Chrissoheris M, Kourkoveli P, Papadopoulos K, Smolka G, Wojakowski W, Reczuch K, Pinto FJ, Zmudka K, Kalarus Z, Adamo M, Santiago-Vacas E, Ruf TF, Gross M, Tongers J, Hasenfuß G, Schillinger W, and Ponikowski P
Subjects: Humans, Female, Male, Aged, Prospective Studies, Treatment Outcome, Middle Aged, Peptide Fragments blood, Mitral Valve surgery, Natriuretic Peptide, Brain blood, Heart Valve Prosthesis Implantation methods, Ventricular Function, Left physiology, Mitral Valve Insufficiency surgery, Mitral Valve Insufficiency physiopathology, Mitral Valve Insufficiency complications, Heart Failure physiopathology, Heart Failure therapy, Heart Failure complications, Severity of Illness Index, Stroke Volume physiology
Abstract: Aim: The RESHAPE-HF2 trial is designed to assess the efficacy and safety of the MitraClip device system for the treatment of clinically important functional mitral regurgitation (FMR) in patients with heart failure (HF). This report describes the baseline characteristics of patients enrolled in the RESHAPE-HF2 trial compared to those enrolled in the COAPT and MITRA-FR trials., Methods and Results: The RESHAPE-HF2 study is an investigator-initiated, prospective, randomized, multicentre trial including patients with symptomatic HF, a left ventricular ejection fraction (LVEF) between 20% and 50% with moderate-to-severe or severe FMR, for whom isolated mitral valve surgery was not recommended. Patients were randomized 1:1 to a strategy of delivering or withholding MitraClip. Of 506 patients randomized, the mean age of the patients was 70 ± 10 years, and 99 of them (20%) were women. The median EuroSCORE II was 5.3 (2.8-9.0) and median plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 2745 (1407-5385) pg/ml. Most patients were prescribed beta-blockers (96%), diuretics (96%), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (82%) and mineralocorticoid receptor antagonists (82%). The use of sodium-glucose cotransporter 2 inhibitors was rare (7%). Cardiac resynchronization therapy (CRT) devices had been previously implanted in 29% of patients. Mean LVEF, left ventricular end-diastolic volume and effective regurgitant orifice area (EROA) were 31 ± 8%, 211 ± 76 ml and 0.25 ± 0.08 cm 2 , respectively, whereas 44% of patients had mitral regurgitation severity of grade 4+. Compared to patients enrolled in COAPT and MITRA-FR, those enrolled in RESHAPE-HF2 were less likely to have mitral regurgitation grade 4+ and, on average, HAD lower EROA, and plasma NT-proBNP and higher estimated glomerular filtration rate, but otherwise had similar age, comorbidities, CRT therapy and LVEF., Conclusion: Patients enrolled in RESHAPE-HF2 represent a third distinct population where MitraClip was tested in, that is one mainly comprising of patients with moderate-to-severe FMR instead of only severe FMR, as enrolled in the COAPT and MITRA-FR trials. The results of RESHAPE-HF2 will provide crucial insights regarding broader application of the transcatheter edge-to-edge repair procedure in clinical practice., (© 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
Published: 2024
Full Text: View/download PDF

14. Transcatheter aortic valve implantation with self-expanding valves and the impact of balloon predilatation: The DIRECT II trial.

Author: Koliastasis L, Doundoulakis I, Rychter J, Zembala M, Ninios V, Ninios I, Evangelou S, Katsimagklis G, Mastrokostopoulos A, Moraitis S, Komporozos C, Hamilos M, Skalidis E, Syrseloudis D, Pagkalidou E, Benetos G, Latsios G, Drakopoulou M, Synetos A, Aggeli K, Tousoulis D, Tsioufis K, and Toutouzas K
Subjects: Humans, Treatment Outcome, Balloon Valvuloplasty methods, Prosthesis Design, Transcatheter Aortic Valve Replacement methods, Transcatheter Aortic Valve Replacement instrumentation, Aortic Valve Stenosis surgery, Aortic Valve surgery, Heart Valve Prosthesis
Abstract: Competing Interests: Declaration of competing interest The authors have no conflicts of interest to declare.
Published: 2024
Full Text: View/download PDF

15. Comparison of two self-expanding transcatheter heart valves for degenerated surgical bioprostheses: the AVENGER multicentre registry.

Author: Kim WK, Seiffert M, Rück A, Leistner DM, Dreger H, Wienemann H, Adam M, Möllmann H, Blumenstein J, Eckel C, Buono A, Maffeo D, Messina A, Holzamer A, Sossalla S, Costa G, Barbanti M, Motta S, Tamburino C, von der Heide I, Glasmacher J, Sherif M, Seppelt P, Fichtlscherer S, Walther T, Castriota F, Nerla R, Frerker C, Schmidt T, Wolf A, Adamaszek MM, Giannini F, Vanhaverbeke M, Van de Walle S, Stammen F, Toggweiler S, Brunner S, Mangieri A, Gitto M, Kaleschke G, Ninios V, Ninios I, Hübner J, Xhepa E, Renker M, Charitos EI, Joner M, and Rheude T
Subjects: Humans, Catheters, Heart Valves, Registries, Bioprosthesis, Aortic Valve Insufficiency etiology, Aortic Valve Insufficiency surgery, Coronary Occlusion, Transcatheter Aortic Valve Replacement adverse effects
Abstract: Background: There is a lack of comparative data on transcatheter aortic valve implantation (TAVI) in degenerated surgical prostheses (valve-in-valve [ViV])., Aims: We sought to compare outcomes of using two self-expanding transcatheter heart valve (THV) systems for ViV., Methods: In this retrospective multicentre registry, we included consecutive patients undergoing transfemoral ViV using either the ACURATE neo/neo2 (ACURATE group) or the Evolut R/PRO/PRO+ (EVOLUT group). The primary outcome measure was technical success according to Valve Academic Research Consortium (VARC)-3. Secondary outcomes were 30-day all-cause mortality, device success (VARC-3), coronary obstruction (CO) requiring intervention, rates of severe prosthesis-patient mismatch (PPM), and aortic regurgitation (AR) ≥moderate. Comparisons were made after 1:1 propensity score matching., Results: The study cohort comprised 835 patients from 20 centres (ACURATE n=251; EVOLUT n=584). In the matched cohort (n=468), technical success (ACURATE 92.7% vs EVOLUT 88.9%; p=0.20) and device success (69.7% vs 73.9%; p=0.36) as well as 30-day mortality (2.8% vs 1.6%; p=0.392) were similar between the two groups. The mean gradients and rates of severe PPM, AR ≥moderate, or CO did not differ between the groups. Technical and device success were higher for the ACURATE platform among patients with a true inner diameter (ID) >19 mm, whereas a true ID ≤19 mm was associated with higher device success - but not technical success - among Evolut recipients., Conclusions: ViV TAVI using either ACURATE or Evolut THVs showed similar procedural outcomes. However, a true ID >19 mm was associated with higher device success among ACURATE recipients, whereas in patients with a true ID ≤19 mm, device success was higher when using Evolut.
Published: 2024
Full Text: View/download PDF

16. Clinical outcomes of the Myval transcatheter heart valve system in patients with severe aortic valve stenosis: a two-year follow-up observational study.

Author: Kilic T, Ielasi A, Ninios V, Korkmaz L, Panagiotakos D, Yerlikaya G, Ozderya A, Montonati C, Tespili M, Coskun S, Sahin T, Ninios I, Vlasopoulou K, Konus AH, Kul S, and Akyuz AR
Abstract: Introduction: Limited data exist on long-term follow-up of severe aortic stenosis (SAS) patients who have undergone transcatheter aortic valve implantation (TAVI) with a new generation, balloon expandable Myval transcatheter heart valve (THV). Thus, we sought to investigate the performance and 2-year clinical outcome of the Myval THV system based on Valve Academic Research Consortium-3 (VARC-3) criteria., Material and Methods: A multi-centre, registry-based, observational study was conducted, which included 207 consecutive degenerative SAS patients, from Turkey ( n = 128), Italy ( n = 58), and Greece ( n = 21) (mean [standard deviation] 81 (7) years, 94 [45%] men; 73% NYHA III or IV; EuroSCORE II 5.2% [2.4%]); all patients underwent TAVI with Myval. Patients were followed up at 1 year and 2 years after implantation. Clinical and procedural outcomes were defined according to VARC-3 criteria., Results: Technical success was observed in 204 (99%), device success was observed in 189 (91%), early safety was observed in 161 (78%), and clinical efficacy was observed in 163 (79%) patients. The 30-day death rate was 7.7%; of these, 3.4% were due to cardiovascular reasons. All-cause and cardiovascular mortality rates were 9.7% and 4.3% at 1-year follow-up, and 17.4% and 9.7% at 2-year follow-up, respectively. Incidence of ≥ moderate paravalvular leak (PVL) at 30 days, 1 year and 2 years of follow-up were 3.4%, 4.3% and 4.8%. A total of 11.1% of patients required a permanent pacemaker implantation (PPI) at 30 days after implantation, while the cumulative rate of PPI at 2 years was 12.1%., Conclusions: In this cohort of patients with SAS, the Myval was found to be safe and effective in up to 2 years of follow-up., Competing Interests: The authors declare no conflict of interest., (Copyright: © 2024 Termedia & Banach.)
Published: 2024
Full Text: View/download PDF

17. Transcatheter transseptal treatment of patients with severe mitral regurgitation using an atrial fixation mitral valve replacement technology.

Author: Ninios V, Ninios I, Ranard LS, Vahl TP, and Wróbel K
Subjects: Humans, Mitral Valve diagnostic imaging, Mitral Valve surgery, Quality of Life, Cardiac Catheterization, Treatment Outcome, Mitral Valve Insufficiency diagnostic imaging, Mitral Valve Insufficiency surgery, Mitral Valve Insufficiency etiology, Heart Valve Prosthesis Implantation, Heart Valve Diseases surgery, Heart Valve Prosthesis
Abstract: Background: Mitral regurgitation (MR) is the most common valvular heart disease worldwide with a 5-year mortality rate of 50 % with medical therapy alone. Several transcatheter mitral valve replacement (TMVR) devices are being investigated in clinical trials. Early evidence has demonstrated clinical benefits with a reduction in heart failure symptoms, low rates of residual MR, and reverse remodeling of the left ventricle (LV) over time. However, high anatomical screen failure rates limit its applicability. The primary reasons for the anatomical screen failure are risk of LV outflow tract obstruction, large mitral valve annulus size, and the presence of mitral annular calcification. Our clinical experiences using an atrial only fixation TMVR technology delivered via a transfemoral-transseptal approach is described., Methods: Three consecutive patients with severe functional MR underwent TMVR implantation using an atrial only fixation technology and a low-profile transseptal delivery system., Results: Technical success was achieved in 100 % of the patients with a clinically significant reduction in MR. Longer-term follow-up (up to 6-months) has demonstrated a sustained reduction in MR and significant improvement in quality of life for all patients., Conclusions: Longer-term outcomes in our patients showed persistent reduction in MR, sustained implant performance, and notable improvements in NYHA Class and quality of life. There were no major adverse events. Follow-up CT data showed no evidence of device-related thrombosis, with stable valve position and integrity. The atrial fixation TMVR technology may have benefits in preserving the dynamics of the native mitral valve annulus thereby reducing the overall risk of LVOT obstruction., Short Abstract: We present a single-center experience of three consecutive patients with severe functional MR treated with the AltaValve using a low-profile transseptal delivery system. A clinically significant reduction in mitral regurgitation was achieved in all patients, and longer-term follow-up has demonstrated sustained clinical benefits., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:, (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

18. Transcatheter Aortic Valve Implantation with the Portico Valve: 2-Year Outcomes of a Multicenter, Real-World Registry.

Author: Didagelos M, Ninios V, Kakderis C, Lakkas L, Kouparanis A, Nikas D, Naka KK, Rammos A, Zegkos T, Kamperidis V, Ninios I, Evangelou S, Tsalikakis DG, Michalis L, and Ziakas A
Abstract: Introduction: The self-expanding, resheathable, repositionable transcatheter aortic heart valve Portico is being used successfully for transcatheter aortic valve implantation procedures (TAVI) in patients with severe aortic stenosis. The aim of this study was to evaluate outcomes at 2 years after TAVI with the Portico valve., Methods: Multicenter registry of clinical, echocardiographic and survival data from consecutive patients treated with the Portico TAVI system (Abbott, Chicago, IL, USA) in three cath labs in Northern Greece and Epirus during 2017-2020. The primary end point was all-cause mortality at 24 months. Secondary end points included procedural outcomes (efficacy and safety) and echocardiographic measurements., Results: A total of 90 patients (81 ± 6 years, 50% females, mean age 81 ± 6 years) were included in the registry. The indication for implantation was severe, symptomatic aortic stenosis (NYHA III, IV) in eighty-two (91.1%) and degeneration of a prosthetic aortic valve in eight (8.9%) patients. All patients were categorized as high surgical risk (mean Logistic Euroscore 25.9 ± 10, Euroscore II 7.7 ± 4.4 and STS score 10.8 ± 8.9). The procedure was performed transfemorally in all patients, under general anesthesia in 95.6%, under TOE guidance in 21.1%, with native valve predilatation in 46.7%, and the "resheath" option was used in 31.1% of the cases. The implantation was successful in 97.8% and there was a need for a second valve in 2.2% of the cases. Complications included permanent pacemaker implantation (16.7%), access cite complications (15.6%), arrythmias (23.3%), paravalvular leak (moderate 7.8%, severe 1.1%), acute kidney injury (7.8%), no strokes and one death during the procedure. Aortic valve peak velocity, peak and mean pressure gradients, were significantly reduced after the procedure. All-cause mortality at 1, 12 and 24 months was 4.4%, 6.7% and 7.8%, respectively., Conclusions: TAVI with the Portico system comprises an effective and safe solution for the management of severe, symptomatic aortic stenosis in high-risk surgical patients.
Published: 2023
Full Text: View/download PDF

19. Updated knowledge and practical implementations of stress echocardiography in ischemic and non-ischemic cardiac diseases: An expert consensus of the Working Group of Echocardiography of the Hellenic Society of Cardiology.

Author: Kadoglou NPE, Papadopoulos CH, Papadopoulos KG, Karagiannis S, Karabinos I, Loizos S, Theodosis-Georgilas A, Aggeli K, Keramida K, Klettas D, Kounas S, Makavos G, Ninios I, Ntalas I, Ikonomidis I, Sahpekidis V, Stefanidis A, Zaglavara T, Athanasopoulos G, Karatasakis G, Kyrzopoulos S, Kouris N, Patrianakos A, Paraskevaidis I, Rallidis L, Savvatis K, Tsiapras D, and Nihoyannopoulos P
Subjects: Consensus, Echocardiography, Echocardiography, Stress methods, Humans, Cardiology, Heart Diseases
Abstract: Stress echocardiography (SE) is a well established and valid technique, widely used for the diagnostic evaluation of patients with ischemic and nonischemic cardiac diseases. This statement of the Echocardiography Working Group of the Hellenic Society of Cardiology summarizes the consensus of the writing group regarding the applications of SE, based on the expertise of their members and on a critical review of present medical literature. The main objectives of the consensus document include a comprehensive review of SE methodology and training-which focus on the preparation, the protocols used, the analysis of the SE images, and updated, evidence-based knowledge about SE applications on ischemic and nonischemic heart diseases, such as in cardiomyopathies, heart failure, and valvular heart disease., (Copyright © 2021 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.)
Published: 2022
Full Text: View/download PDF

20. Simultaneous implantation of MitraClip devices in a patient with severe mitral and tricuspid valve regurgitation.

Author: Ninios V, Tourmousoglou C, Mezilis N, Ninios I, Dardas P, Tsikaderis D, Theophylogiannakos S, and Pitsis A
Subjects: Aged, 80 and over, Cardiac Catheterization, Echocardiography, Equipment Design, Humans, Male, Mitral Valve diagnostic imaging, Mitral Valve Insufficiency complications, Mitral Valve Insufficiency diagnosis, Tricuspid Valve surgery, Tricuspid Valve Insufficiency complications, Tricuspid Valve Insufficiency diagnosis, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation instrumentation, Heart Valve Prosthesis Implantation methods, Mitral Valve surgery, Mitral Valve Insufficiency surgery, Tricuspid Valve diagnostic imaging, Tricuspid Valve Insufficiency surgery
Abstract: We present a case of an 84-year old patient with severe mitral and tricuspid regurgitation with a lot of cormobidities who underwent a simultaneous transfemoral (one approach) mitral and tricuspid valve repair using the MitraClip system., (Copyright © 2018 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.)
Published: 2019
Full Text: View/download PDF

21. Is there a prognostic relevance of electrophysiological studies in bundle branch block patients?

Author: Bogossian H, Frommeyer G, Göbbert K, Hasan F, Nguyen QS, Ninios I, Mijic D, Bandorski D, Hoeltgen R, Seyfarth M, Lemke B, Eckardt L, and Zarse M
Subjects: Aged, Aged, 80 and over, Bundle-Branch Block mortality, Bundle-Branch Block physiopathology, Bundle-Branch Block therapy, Cardiac Pacing, Artificial, Disease-Free Survival, Electrocardiography, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Predictive Value of Tests, Reproducibility of Results, Risk Factors, Time Factors, Action Potentials, Bundle of His physiopathology, Bundle-Branch Block diagnosis, Electrophysiologic Techniques, Cardiac, Heart Rate
Abstract: Background: The present European guidelines suggest a diagnostic electrophysiological (EP) study to determine indication for cardiac pacing in patients with bundle branch block and unexplained syncope. We evaluated the prognostic relevance of an EP study for mortality and the development of permanent complete atrioventricular (AV) block in patients with symptomatic bifascicular block and first-degree AV block., Hypothesis: The HV interval is a poor prognostic marker to predict the development of permanent AV block in patients with symptomatic bifascicular block (BFB) and AV block I°., Methods: Thirty consecutive patients (mean age, 74.8 ± 8.6 years; 25 males) with symptomatic BFB and first-degree AV block underwent an EP study before device implantation, according to current guidelines. For 53 ± 31 months, patients underwent yearly follow-up screening for syncope or higher-degree AV block., Results: Thirty patients presented with prolonged HV interval during the EP study (mean, 82.2 ± 20.1 ms; range, 57-142 ms), classified into 3 groups: group 1, <70 ms (mean, 62 ± 4 ms; range, 57-67 ms; n = 7), group 2, >70 to ≤100 ms (mean, 80 ± 8 ms; range, 70-97 ms; n = 18), and group 3, >100 ms (mean, 119 ± 14 ms; range, 107-142 ms; n = 5). According to the guidelines, patients in groups 2 and 3 received a pacemaker. The length of the HV interval was not associated with the later development of third-degree AV block or with increased mortality., Conclusions: Our present study suggests that an indication for pacemaker implantation based solely on a diagnostic EP study with prolongation of the HV interval is not justified., (© 2017 Wiley Periodicals, Inc.)
Published: 2017
Full Text: View/download PDF

22. A new experimentally validated formula to calculate the QT interval in the presence of left bundle branch block holds true in the clinical setting.

Author: Bogossian H, Frommeyer G, Ninios I, Pechlivanidou E, Hasan F, Nguyen QS, Mijic D, Kloppe A, Karosiene Z, Margkarian A, Bandorski D, Schultes D, Erkapic D, Seyfarth M, Lemke B, Eckardt L, and Zarse M
Subjects: Bundle of His physiopathology, Humans, Reproducibility of Results, Retrospective Studies, Risk Factors, Treatment Outcome, Bundle-Branch Block physiopathology, Electrocardiography methods
Abstract: Background: The evaluation of the QT interval in the presence of left bundle branch block (LBBB) is associated with the challenge to discriminate native QT interval from the prolongation due to the increase in QRS duration. The newest formula to evaluate QT interval in the presence of LBBB suggests: modified QT during LBBB = measured QT interval minus 50% of LBBB duration. The purpose of this study is therefore to validate the abovementioned formula in the clinical setting., Methods: Validation in two separate groups of patients: Patients who alternated between narrow QRS and intermittent LBBB and patients with narrow QRS who developed LBBB after transcatheter aortic valve implantation (TAVI)., Results: The acquired mean native QTc intervals and those calculated by the presented formula displayed no significant differences (p > .99 and p > .75)., Conclusions: In this study we proved for the first time the validity and applicability of the experimentally acquired formula for the evaluation of the QT interval in the presence of LBBB in a clinical setting., (© 2016 Wiley Periodicals, Inc.)
Published: 2017
Full Text: View/download PDF

23. Expression of NO Synthase Under Medication with Cyclosporine A, Mycophenolate Mofetil, and Tacrolimus during Development of Transplant Vasculopathy on Rat Cardiac Allograft.

Author: Bogossian H, Frommeyer G, Ninios I, Bandorski D, Seyfarth M, Matzaroglou C, Lemke B, Eckardt L, Zarse M, and Kafchitsas K
Subjects: Allografts, Animals, Coronary Artery Disease enzymology, Coronary Artery Disease immunology, Coronary Vessels enzymology, Disease Models, Animal, Down-Regulation, Graft Rejection enzymology, Graft Rejection immunology, Graft Survival drug effects, Nitric Oxide metabolism, Rats, Inbred Lew, Time Factors, Coronary Artery Disease prevention & control, Coronary Vessels drug effects, Cyclosporine pharmacology, Graft Rejection prevention & control, Heart Transplantation adverse effects, Immunosuppressive Agents pharmacology, Mycophenolic Acid pharmacology, Nitric Oxide Synthase Type II metabolism, Nitric Oxide Synthase Type III metabolism, Tacrolimus pharmacology
Abstract: Objective: The transplant vasculopathy as a sign of chronic graft rejection affects both the epicardial and the intramyocardial arteries of the graft. This is at least partially mediated by NO synthases. The aim of this study was to assess possible protective effects of cyclosporine A (CsA), tacrolimus (FK506), and mycophenolate mofetil (MMF) on the expression of NO synthases in an experimental transplant rat model., Aims: Heart transplantation was performed in 322 rats. These were randomly assigned to four equal groups (control, CsA, FK506, MMF). Recipients were monitored up to 60 days after transplantation, while transplanted hearts were recovered at certain time points for analysis. Expression and staining intensity for endothelial nitric oxide synthases (e-nos) and inducible nitric oxide synthases (i-nos) were analyzed in epicardial and intramyocardial vessels in each group., Results: All employed drugs led to a significant reduction of expression or staining intensity of i-nos and e-nos. MMF was most effective in reduction in expression of both NO synthases., Conclusions: These results imply that all described drugs prevent endothelial impairment induced by toxicity of NO and thereby prevent transplant vasculopathy. MMF seems to be the most effective drug., (© 2016 John Wiley & Sons Ltd.)
Published: 2016
Full Text: View/download PDF

24. Spot diagnosis of inferior axis and concordant R-pattern predicts left ventricular inflow tract tachycardia: Ablation from the great cardiac vein of an underdiagnosed entity.

Author: Bogossian H, Frommeyer G, Ninios I, Hasan F, Nguyen QS, Karosiene Z, Mijic D, Bandorski D, Seyfarth M, Friemann J, Lemke B, Eckardt L, and Zarse M
Subjects: Cohort Studies, Electrocardiography methods, Humans, Predictive Value of Tests, Retrospective Studies, Tachycardia, Ventricular physiopathology, Ventricular Premature Complexes diagnostic imaging, Ventricular Premature Complexes physiopathology, Ventricular Premature Complexes surgery, Catheter Ablation methods, Coronary Vessels diagnostic imaging, Coronary Vessels surgery, Tachycardia, Ventricular diagnostic imaging, Tachycardia, Ventricular surgery
Abstract: Background: The present literature holds an enormous variation concerning origin and ablation site of idiopathic ventricular arrhythmias (VA), ranging from 2.5 to 15% for the origin within the coronary venous system (CVS). The aim of the study was to detect positive predictive ECG morphology patterns to discriminate VA stemming from the CVS., Methods: 110 consecutive patients (P) with 111 premature ventricular capture beat (PVC) morphologies undergoing successful ablation for VA were retrospectively analyzed concerning their ECG patterns., Results: 20/110 P (18%) displayed their VA origin in the CVS with anterior/anterolateral left ventricular inflow tract (LVIT) (epicardial/GCV) in 16 P (14%), anterior/anterolateral LVIT (endo- and epicardial/GCV) in 3 P (3%), and anterior interventricular vein (AIV) 1 P (<1%). ECG morphology of all GCV cases demonstrated an inferior axis and concordant R-pattern in all precordial leads resulting in 100% sensitivity. One VA demonstrating this pattern was ablated outside at the LVOT resulting in 95% specificity for origin in the anterior/anterolateral LVIT. 3/20 P that were ablated in the CVS required additional endocardial ablation from the anterior/anterolateral LVIT resulting in 80% specificity for sole successful ablation in the CVS., Conclusion: An inferior axis and concordant R-pattern in all precordial leads serve as diagnostic markers for an LVIT origin in the surface ECG and suggest a high primary ablation success via the GCV., (Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.)
Published: 2016
Full Text: View/download PDF

25. Q Wave in the Inferior Leads: There Is More Than Scar.

Author: Bogossian H, Ninios I, Frommeyer G, Mijic D, Hasan F, Bandorski D, Eckardt L, Lemke B, and Zarse M
Subjects: Adult, Cicatrix diagnosis, Female, Humans, Myocardial Infarction diagnosis, Electrocardiography, Hypertrophy, Left Ventricular diagnosis, Hypertrophy, Left Ventricular etiology
Abstract: Q waves can regularly be observed in the 12-lead electrocardiogram either due to heart axis underlying pathology such as subacute myocardial infarction, myocardial scar, or accessory pathways. Rarely, other entities such as circumscribed hypertrophy can induce significant Q wave and represent an important differential diagnosis especially in younger patients. In the setting of atypical chest pain determination of the correct diagnosis can be challenging. Therefore, circumscribed hypertrophy should be taken into account to avoid unnecessary invasive procedures., (© 2015 Wiley Periodicals, Inc.)
Published: 2015
Full Text: View/download PDF

26. U wave during supraventricular tachycardia: simulation of a long RP tachycardia and hiding the common type AVNRT.

Author: Bogossian H, Ninios I, Frommeyer G, Bandorski D, Eckardt L, Lemke B, and Zarse M
Subjects: Diagnosis, Differential, Female, Humans, Middle Aged, Electrocardiography, Tachycardia, Atrioventricular Nodal Reentry diagnosis, Tachycardia, Atrioventricular Nodal Reentry physiopathology, Tachycardia, Supraventricular diagnosis, Tachycardia, Supraventricular physiopathology
Abstract: The main tool for the differentiation of supraventricular tachycardia is the 12-lead electrocardiogram (ECG). Especially differentiating the atrioventricular nodal reentrant tachycardia (AVNRT) from the atrioventricular reentrant tachycardia (AVRT) due to concealed accessory pathway or from an atrial tachycardia (AT) is very important for catheter setting and ablation approach in an electrophysiological study. In our case we saw the occurrence of a U wave during tachycardia-simulating a pseudo P wave. This mimicked a long RP-tachycardia, although it was a common type AVNRT., (© 2014 Wiley Periodicals, Inc.)
Published: 2015
Full Text: View/download PDF

27. New formula for evaluation of the QT interval in patients with left bundle branch block.

Author: Bogossian H, Frommeyer G, Ninios I, Hasan F, Nguyen QS, Karosiene Z, Mijic D, Kloppe A, Suleiman H, Bandorski D, Seyfarth M, Lemke B, Eckardt L, and Zarse M
Subjects: Adult, Aged, Bundle-Branch Block therapy, Cohort Studies, Comorbidity, Electrocardiography methods, Evaluation Studies as Topic, Female, Follow-Up Studies, Forecasting, Germany, Humans, Long QT Syndrome therapy, Male, Middle Aged, Risk Assessment, Sensitivity and Specificity, Severity of Illness Index, Survival Rate, Time Factors, Bundle-Branch Block diagnosis, Bundle-Branch Block epidemiology, Electrocardiography trends, Long QT Syndrome diagnosis, Long QT Syndrome epidemiology
Abstract: Background: Left bundle branch block (LBBB) and QT prolongation both are associated with a worse prognosis. LBBB lengthens the QT interval. To date it is not known whether QT prolongation during LBBB differs in repolarization from QT prolongation during narrow QRS., Objective: The purpose of the present proof-of-concept-study was to develop a formula that allows comparison of the adjusted QT interval during LBBB with reference values and thereby allows interpretation of the QT interval irrespective of QRS widening., Methods: Sixty consecutive patients with sinus rhythm (SR) and narrow QRS underwent electrophysiologic study for ablation. In all patients, the intrinsic QRS ,QT, and JT times were measured during SR, and ventricular pacing from both the right ventricular apex (RVA) and the right ventricular outflow tract (RVOT) caused LBBB. We determined prolongation of the QT during as compared to SR (ΔQT). ΔQT was then divided by the QRS length during pacing QRS (QRSb). This describes the percentage of the QRS duration at LBBB, which must be subtracted from the measured QT (QTb) to determine the modified QT interval (QTm)., Results: The ratio of ΔQT to paced QRS was calculated as 48.3% (RVA) and 48.8% (RVOT) (mean 48.5%). The ratio intrinsic of JTi to paced JT was 1.0055 (RVA) and 1.0087 (RVOT). There was no significant difference in intrinsic JT vs paced JT (P = .2)., Conclusion: Right ventricular pacing causes prolongation of the QT due to a paced LBBB without prolongation of the JT time. In our study, we showed that QT prolongation caused by LBBB constitutes 48.5% of the QRS width. This is the value that must be subtracted from the measured QT in LBBB in order to estimate the modified QT. Thus, the resulting formula for "modified QT" estimation in LBBB is QTm = QTb - 48.5% * (QRSb)., (Copyright © 2014 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
Published: 2014
Full Text: View/download PDF

28. Prevalence, clinical correlates and treatment of permanent atrial fibrillation among the elderly: insights from the first prospective population-based study in rural Greece.

Author: Ninios I, Bogossian H, Zarse M, Lazaridou F, Dimitriadis K, Ninios V, Lemke B, and Louridas G
Subjects: Age Factors, Aged, Anticoagulants therapeutic use, Atrial Fibrillation drug therapy, Female, Greece epidemiology, Humans, Male, Platelet Aggregation Inhibitors therapeutic use, Prevalence, Prospective Studies, Rural Population, Atrial Fibrillation epidemiology
Abstract: To investigate the prevalence of permanent atrial fibrillation (AF), its clinical associated conditions and treatment status in the elderly population in rural Greece. 720 people (46.1% males) older than 65 years (mean age: 72.5 +/- 5.7 years) living in four villages in rural Greece were screened with an electrocardiogram (response rate: 90.5%) for the presence of permanent AF. They underwent a physical examination, including blood pressure (BP) measurement, and body mass index (BMI) calculation, in addition to an interview about their medical history, physical activity, smoking habits, alcohol consumption and medication use. Subjects with AF for whom anticoagulants were contraindicated were identified and stroke risk stratification was performed using the CHADS2 algorithm. The prevalence of permanent AF was 5% (6.6% among men and 3.6% among women) and it increased with age. In the entire population, ECG evidence of myocardial ischaemia and ventricular premature beats were independently associated with the presence of permanent AF (OR 5.266; 95% CI 2.22-12.49, P = 0.0001 and OR 2.61; 95% CI 1.059-6.432, P = 0.037, respectively), while female sex was independently associated with the absence of the AF (OR 0.327; CI 0.147-0.729, P = 0.006). From those patients who were eligible for anticoagulation, 40.6% were treated with anticoagulants, 34.3% were given antiplatelets therapy and the rest received no antithrombotic treatment. This is the first prospective study demonstrating the prevalence, clinical correlates and treatment status of permanent AF in Greece. These results confirm the high prevalence of permanent AF among the elderly and underscore the issue regarding anticoagulants underutilization.
Published: 2010
Full Text: View/download PDF

29. Gender-specific differences in hypertension prevalence, treatment, control, and associated conditions among the elderly: data from a Greek population.

Author: Ninios I, Ninios V, Lazaridou F, Dimitriadis K, Kerasidou O, and Louridas G
Subjects: Age Distribution, Aged, Body Mass Index, Cardiovascular Diseases epidemiology, Cohort Studies, Comorbidity, Diabetes Mellitus epidemiology, Electrocardiography, Female, Greece epidemiology, Humans, Hypertension diagnosis, Interviews as Topic, Male, Prevalence, Risk Factors, Rural Population, Sex Distribution, Treatment Outcome, Hypertension epidemiology, Hypertension prevention & control
Abstract: Purpose: In the present study we sought to assess the gender-specific prevalence, treatment rates, and control of hypertension, as well as to identify its associated conditions and additional cardiovascular (CV) risk factors, in a Greek population aged > or = 65 years old., Methods: This is a population-based study including a clinical interview, an ECG recording, and blood pressure (BP) measurements by sphygmomanometer., Results: The overall prevalence of hypertension was 83.3%, higher in females and increasing with age. In males, hypertension was independently associated with increased body mass index (BMI), a history of stroke, and myocardial infarction, while in females increased age, BMI, and a history of diabetes were independently associated with hypertension. A considerable proportion of hypertensives were treated (77.3%), while an effective control of BP was achieved in 42.5% of treated subjects. Despite the fact that hypertension treatment rates did not differ between the genders, control rates were lower among females. Finally, more hypertensive females presented additional CV risk factors than normotensives., Conclusion: Elderly females exhibit a higher prevalence of hypertension and are characterized by lower hypertension control compared to hypertensive males.
Published: 2008
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

29 results on '"Ninios I"'

1. 470 Cardiac Computed Tomography Prior And After A Transcatheter Occlusion Of An Aortic Pseudoaneurysm With The Amplatzer Device: A Case Report

2. Impending total AV-block in chronic bifascicular block -Risk assessment via symptoms and 12 lead ECG

3. The transseptal acces increases safety and efficacy of substrate modification for ventricular tachycardia

4. A new combined stylet/guide wire-tool for left ventricular lead placement for cardiac resynchronisation therapy

5. Fractured Bioprosthetic Pulmonary Valve Identified By Cardiac Computed Tomography Followed By Transcatheter Replacement

6. Prevalence, clinical correlates and treatment of permanent atrial fibrillation among the elderly: Insights from the first prospective population-based study in rural Greece

7. Poster Session 3

8. Poster Session 2

9. Prevalence of interatrial block in a general population of elderly people.

10. Safety and Efficacy in Mitral Regurgitation Management with the MitraClip ® G4 System: Insights from a Single-Center Study.

11. Hospitalization of Symptomatic Patients With Heart Failure and Moderate to Severe Functional Mitral Regurgitation Treated With MitraClip: Insights From RESHAPE-HF2.

12. Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation.

13. Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials.

14. Transcatheter aortic valve implantation with self-expanding valves and the impact of balloon predilatation: The DIRECT II trial.

15. Comparison of two self-expanding transcatheter heart valves for degenerated surgical bioprostheses: the AVENGER multicentre registry.

16. Clinical outcomes of the Myval transcatheter heart valve system in patients with severe aortic valve stenosis: a two-year follow-up observational study.

17. Transcatheter transseptal treatment of patients with severe mitral regurgitation using an atrial fixation mitral valve replacement technology.

18. Transcatheter Aortic Valve Implantation with the Portico Valve: 2-Year Outcomes of a Multicenter, Real-World Registry.

19. Updated knowledge and practical implementations of stress echocardiography in ischemic and non-ischemic cardiac diseases: An expert consensus of the Working Group of Echocardiography of the Hellenic Society of Cardiology.

20. Simultaneous implantation of MitraClip devices in a patient with severe mitral and tricuspid valve regurgitation.

21. Is there a prognostic relevance of electrophysiological studies in bundle branch block patients?

22. A new experimentally validated formula to calculate the QT interval in the presence of left bundle branch block holds true in the clinical setting.

23. Expression of NO Synthase Under Medication with Cyclosporine A, Mycophenolate Mofetil, and Tacrolimus during Development of Transplant Vasculopathy on Rat Cardiac Allograft.

24. Spot diagnosis of inferior axis and concordant R-pattern predicts left ventricular inflow tract tachycardia: Ablation from the great cardiac vein of an underdiagnosed entity.

25. Q Wave in the Inferior Leads: There Is More Than Scar.

26. U wave during supraventricular tachycardia: simulation of a long RP tachycardia and hiding the common type AVNRT.

27. New formula for evaluation of the QT interval in patients with left bundle branch block.

28. Prevalence, clinical correlates and treatment of permanent atrial fibrillation among the elderly: insights from the first prospective population-based study in rural Greece.

29. Gender-specific differences in hypertension prevalence, treatment, control, and associated conditions among the elderly: data from a Greek population.

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

29 results on '"Ninios I"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources